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INVESTIGATION OF VIRAL GENETIC AND BIOLOGIC DETERMINANTS OF 
HIV-1 SUBTYPE C PREDOMINANCE IN INDIA 
Milka A. Rodriguez, PhD 
University of Pittsburgh, 2007
 
In India, HIV-1 subtype C has been the predominant subtype throughout the course of the HIV-1 
epidemic, regardless of geographic region in the country. We hypothesize that the dominance of 
HIV-1 subtype C compared to other subtypes in India is due to enhanced replication fitness 
and/or enhanced transmission efficiency of this subtype across the mucosal surface over other 
subtypes present in India. The specific aims of this project are: (1) to compare the replication 
fitness between Indian HIV-1 subtype A and subtype C; (2) to evaluate the transmission 
efficiency of Indian HIV-1 subtype A and subtype C across the mucosa of cervical tissue; and (3) 
to determine the role of the LTR and env gene in replication fitness and transmission efficiency. 
Replication fitness was assessed using a dual infection growth competition assay. We observed 
that primary HIV-1 subtype C isolates had higher overall relative fitness and transmission 
efficiency than primary subtype A isolates in PBMC and in an ex vivo cervical tissue derived 
organ culture, respectively. Furthermore, a comparison of replicative fitness between a subtype 
A/subtype C half genome chimeric virus and  parental subtype A virus indicates that the higher 
replication fitness and transmission efficiency of subtype C virus over subtype A virus from 
India is not due to the env gene alone. We have also characterized the genetic structure and 
functional characteristics of subtype A and subtype C LTRs from India.  Despite their apparent 
variability, no significant difference was observed in the transcriptional activity between the 
LTRs of subtype A and subtype C. Therefore, the LTR region alone is not responsible for higher 
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replication fitness of subtype C over subtype A. The findings presented in this study are 
significant for public health because an understanding of the mechanism of the asymmetric 
distribution of HIV-1 subtypes in India is an important component in the development of 
strategies to control HIV-1 infection in this country. 
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1.1 
1.0  INTRODUCTION 
HIV VIRUSES AND THE GLOBAL EPIDEMIC 
Human immunodeficiency virus (HIV), the causative agent of acquired immune deficiency 
syndrome (AIDS) in the human population, is a member of the genus Lentivirus in the family 
Retroviridae. HIV-1 is responsible for the current pandemic, having spread to more than 150 
countries on six continents (1). The spread of HIV-2 has not been nearly as extensive as HIV-1 
although infections have been reported in Europe, the United States and South America and 
accounts for a substantial number of infections in West Africa (1, 2). There are currently an 
estimated 40 million people worldwide living with HIV/AIDS (Figure 1) (3).  Forty-nine percent 
are men, forty-five percent are women and approximately six percent are children under 15 years 
old (3). The major route of HIV transmission is through heterosexual contact, although injection 
drug use, men who have sex with men and mother-to-child transmission also constitute a 
considerable fraction of transmission groups in some countries (1, 2). 
Adapted from publicly available data from UNAIDS and WHO. www.unaids.org. The colors depict regional patterns of HIV variation which are also indicated 
by letters in each region.  Photo/ illustration is reprinted with permission from Francine E. McCutchan and Henry M. Jackson Foundation (Rockville, Maryland) 
©2006 the International AIDS Vaccine Initiative (IAVI). 
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Figure 1.  Global numbers of adults and children estimated to be living with HIV in 2006.  
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1.2 CLASSIFICATION OF HIV-1 
HIV-1 was introduced into the human population through three separate cross-species 
transmissions from a Pan troglodytes troglodytes chimpanzee reservoir in central Africa (4). 
Each of these transmission events is represented by phylogenetic groups termed group M (main), 
group O (outlier) and group N (non-M, non-O) (Figure 2). Considerable diversification has 
evolved within these groups - and especially in group M - due to the error prone nature of the 
reverse transcriptase (RT) enzyme which can introduce approximately 1 mutation per genome, 
per round of replication. This coupled with high viral turnover by which 109 - 1010 virions are 
produced per day creates a swarm of genetically diverse but related populations termed 
quasispecies (5, 6). An additional factor contributing to viral evolution is recombination which 
can occur by way of alternate copying of viral RNA strands by RT. The crossover frequency 
ranges from 7 to 30 per genome per replication round (7).  
 
HIV-1
Group M
Group N Group O
Subtypes (Clades)
A-D, F-H, J, K and CRF’s
Most Predominant Subtypes
A, B, C, D, CRF_AE, CRF_AG  
Figure 2. Classification of HIV-1 genetic forms 
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The high genetic diversity of HIV-1 has lead to further sub-classification of the viral 
groups. HIV-1 Group M, which is responsible for the global pandemic, is further subdivided into 
nine genetic groups called subtypes or clades, based on sequence diversity in the envelope gene 
(Figure 2). All Group M subtypes, namely A – D, F – H, J and K, are believed to have originated 
in Central Africa. At least three epidemiologically unlinked sequences are required to define a 
subtype (1). Intrasubtype amino acid diversity in the envelope gene ranges from 5-20% and 
intersubtype diversity ranges from 25-35%. There is also a growing percentage of the HIV-1 
epidemic that is now comprised of circulating recombinant forms (CRFs). CRFs, of which at 
least 20 have now been classified, are the product of intersubtype recombination events. 
1.3 GLOBAL DISTRIBUTION OF HIV-1 GENETIC FORMS 
Group M viruses are responsible for the global pandemic whereas group O viruses are mainly 
found in Cameroon and some neighboring countries and group N viruses have been reported 
exclusively in Cameroon. Among the group M subtypes the most predominant are A, B, C and D 
and CRF01_AE and CRF02_AG (7). Subtype A is concentrated in East and West Africa, Eastern 
Europe and Central Asia and subtype B in the Americas, Western Europe and Australia. Subtype 
C which has become the most predominant subtype worldwide is concentrated in Southern and 
Eastern Africa and India. Subtype D is also prevalent in East and West Africa. CRF01_AE is the 
predominant subtype throughout Southeast Asia and CRF02_AG has emerged as the dominant 
subtype in West and West Central Africa (1, 7) (Figure 1). Geographically, there appears to be 
an asymmetric distribution of HIV-1 subtypes. Some explanations for this unequal spread of 
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HIV-1 subtypes include founder effects, social and behavioral practices, human genetic 
susceptibility and viral attributes such as transmission efficiency and replication fitness. 
1.4 BIOLOGY OF HIV-1 
This section describes the basic structure and genomic organization of HIV, the HIV life cycle 
and HIV pathogenesis.  
1.4.1 HIV Virion Structure and Genomic Organization 
The HIV virion is 100 to 120 nm in diameter (2) (Figure 3A). It is composed of two RNA strands 
that are surrounded by a conical shaped core which is composed of gag-p24 capsid protein. The 
viral RNA-dependent DNA polymerase (RT) and nucleocapsid proteins are closely associated 
with the genomic RNA within the core. Outside of the core lie accessory and structural proteins 
involved in early and late events in the replication cycle. The exact locations of the vif and nef 
proteins are unclear, although they are closely associated with the core. Vif promotes infectivity 
and aids in proviral DNA synthesis and maturation while nef has been reported to either increase 
or decrease virus replication. Vpr is found outside the core and has several functions involved in 
virus replication, regulation of cell cycling and viral transactivation. The matrix protein is 
located just below the viral membrane and functions in viral maturation and budding (8). The 
entire virus particle is surrounded by a lipid bilayer membrane which it obtains upon budding 
from an infected cell. Finally, embedded in the viral membrane is the envelope glycoprotein 
composed of a gp120 and gp41 subunit. These proteins form trimers, referred to as spikes, on the 
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surface of the virus. The gp120 subunit binds to the host cell CD4 receptor and a coreceptor to 
gain entry into a cell. The gp41 subunit is a transmembrane protein that is noncovalently bound 
to gp120. It is involved in conformational changes in the envelope protein necessary for 
membrane fusion and in envelope glycoprotein incorporation into maturing virions (2). 
The HIV genome is approximately 10kb and contains 9 genes which code for 15 proteins 
(Figure 3B). At the 5’ end of the genome lies the long terminal repeat (LTR) which is also 
duplicated at the 3’ end. The LTR functions as the viral promoter containing several transcription 
factor binding sites that modulate virus replication. Following the 5’ LTR are the gag and pol 
genes. The gag precursor is cleaved into MA, p17; CA, p24; p7, p6, p2 and p1 proteins. The pol 
precursor is cleaved into 3 enzymes – protease (PR), reverse transcriptase (RT) and integrase 
(IN). Protease functions in posttranslational processing of viral proteins. Reverse transcriptase 
generates cDNA from the viral RNA genome and also contains an RNase H domain that 
functions during reverse transcription. Following pol are the accessory genes which code for the 
vif, vpr and vpu (vpx is the vpr homolog in HIV-2) proteins. These accessory proteins serve a 
variety of functions throughout the virus life cycle. The regulatory proteins Tat and Rev are 
generated from multiply spliced mRNA regions of the envelope gene. The env precursor gp160 
is cleaved into gp120 and gp41 proteins. The viral protein Nef is partially encoded in the 3’LTR. 
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5’ LTR p17   p24       p7 p6
PR         p51(RT)         p15  p31(IN) gp120 gp41
vif
vpr
vpu
nef
3’ LTR
rev
tat
gag
pol env  
B) 
Figure 3. HIV-1 virion structure and genomic organization 
A) Mature HIV-1 virion structure. Image was reproduced from a publicly available source from the Los Alamos 
National Laboratory HIV Database, Los Alamos, New Mexico. www.hiv.lanl..gov.  B) HIV-1 genomic structure. 
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1.4.2 The HIV Life Cycle 
HIV enters a cell by binding of its surface gp120 protein to CD4 and a chemokine receptor 
(mainly CCR5 or CXCR4) on the host cell (2). This binding promotes a conformational change 
which induces fusion of the virus to the target cell membrane followed by subsequent release of 
the viral core into the cell. In the cytoplasm the viral RNA is reverse transcribed into cDNA by 
RT and a host of additional viral and cellular proteins (9). The viral cDNA is then transported to 
the nucleus where it can become integrated into the host chromosome. Transcription of the viral 
genome occurs in the nucleus of the host cell mediated by the viral LTR and several host cell 
transcription factors. Following the synthesis of viral proteins and shuttling of full-length copies 
of the viral RNA genome to the cytoplasm, the virion is assembled at the plasma membrane 
where budding occurs (10). 
1.4.3 HIV pathogenesis 
In 1983 HIV was first identified as the causative agent of AIDS. Acute infection by HIV is 
characterized by flu-like symptoms which present within 1 to 4 weeks of infection. These 
symptoms include sore throat, fever, muscle ache, swollen lymph nodes and rash (2). The 
asymptomatic or chronic phase in which there is low level virus replication and no apparent 
illness is unique for each individual and can range from 3 to more than 14 years (11, 12). The 
symptomatic phase generally presents within 10 years after infection and is characterized by high 
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viral loads, high genetic diversity, increased viral replication fitness, low CD4+ T cells numbers 
and a variety of immune disorders (11, 13) (Figure 4).  
Upon transmission to a new host, HIV targets CCR5+ CD4+ effector memory T cells (14, 
15). These target cells are majorly present at mucosal sites such as the gut and cervicovaginal 
mucosa. This results in massive depletion of these immune cells at these mucosal sites within the 
first few weeks of acute infection (14-16). Mucosal depletion is soon followed by a state of 
chronic activation resulting in 1) increased numbers of activated and memory T cells, 2) 
increased production of proinflammatory cytokines and 3) increased turnover of immune cells 
(14). During the acute phase, viremia can be very high (106 to 107 copies/ml) in plasma and 
peripheral blood (2, 17). Over 10 million to 100 million infected CD4+ cells die per day (2, 18). 
The CD8+ T cell response is also high during acute infection and its ability to control viremia 
during the acute phase is usually the best predictor of a long-term asymptomatic period (2).  
Virus infection is established once the infection has traveled from the initial site to local 
lymph nodes. Although a robust immune response is mounted soon after infection with the 
infiltration of CD8+ T cells and production of proinflammatory cytokines and chemokines, it is 
generally too late and the infection is already well established (2). Seroconversion normally 
occurs 1 to 3 weeks after infection and viral set point is reached usually after 3 to 5 months.   
At 3 to 6 months after primary infection, CD4+ T cell numbers increase, however they 
never fully recover to pre-infection levels. This period begins the asymptomatic or chronic phase 
of infection. The decrease in viremia could be due to an immune response mediated by CD8+ T 
cell killing of virus infected cells, substrate exhaustion due to the massive loss of target cells or a 
combination of both. During this time until the symptomatic phase begins (8 to 10 years in a 
typical progressor), there is persistent low level virus replication in the lymph nodes and 
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peripheral blood, increased viral genetic diversity and increased viral replicative fitness  (Figure 
4). Low level virus replication is maintained by an antiviral CD8+ T cell response.  
The symptomatic phase is characterized by increased viral load, a decline in CD4+ T cells 
to less than 200 cells/ul and a deteriorated CD8+ T cell response. In the lymph nodes there is 
massive breakdown of the tissue architecture and destruction of follicular dendritic cells. All of 
these events directly precede or coincide with the emergence of more pathogenic fast replicating 
viruses and CXCR4 coreceptor using viruses (in approximately 50% of cases) and AIDS related 
malignancies. 
Changes in replication fitness and genetic diversity, CD4+ T cell count in the blood and the mucosa and viral loads are shown during HIV disease progression. 
During the acute phase there is high viral load, rapid depletion of CD4+ T cells in the mucosa and an initial decrease in replication fitness followed by an 
increase in fitness upon viral escape of the innate immune response. During the chronic phase, HIV adaptive immunity escape occurs and replication fitness 
increases. All CD4+ T cells are depleted during the AIDS stage, and the viral load increases. Fitness remains high, but HIV diversity is low. Reprinted with 
permission Current Medicine Group, LLC from Henry KR, et al. 2007. The impact of viral and host elements on HIV fitness and disease progression. Curr 
HIV/AIDS Rep 4(1):36-41. Copyright © 2007 Current Medical Group, Philadelphia, PA. All rights reserved.  
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Figure 4. HIV-1 fitness and disease progression model.  
 
 
 1.5 HIV-1 IN INDIA 
1.5.1 India’s HIV epidemic 
According to the UNAIDS 2006 report, India – which has a population of about 1.1 billion, has 
approximately 5.7 million people living with HIV-1. This makes India the second largest HIV-1 
infected population in the world next to South Africa. The highest prevalence rates are found in 
the industrialized south and west in the states of coastal Andhra Pradesh, the Nammakkal district 
of Tamil Nadu, Mumbai-Karnataka corridor, and the Nagpur area of Maharashtra; and in the 
northeastern tip of the country in the states of Nagaland and Manipur (3, 19) (Figure 5).  
  12
 Figure 5. HIV-1 prevalence in India 
Map of India showing HIV-1 prevalence and the Golden Quadrilateral Highway. Reprinted with permission from 
the Massachusetts Medical Society from Steinbrook, R. HIV in India--a complex epidemic. 2007. N Engl J Med 
356(11):1089-93. Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
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 The Golden Quadrilateral Highway is an express highway that connects India’s four 
largest cities. It is through this highway network (among other means) that migrant workers, 
truck drivers and traveling sex workers can contract HIV-1 and spread the virus to different parts 
of the country (19) (Figure 5). Although prostitution, homosexuality and injection drug use are 
all illegal in India, these are the major routes of HIV-1 transmission. Sexual contact accounts for 
roughly 85% of transmissions of the virus (19, 20) a growing proportion of which is from men 
who have sex with men (MSM) (21). Injection drug use follows as the next major contributor to 
the spread of HIV-1 in India (3, 19, 22). Additional routes of transmission are perinatally, via 
breast-feeding and through paid blood donations. Beginning in the early 1990’s, intervention 
projects were started among small groups to bring awareness to sex workers about the modes of 
transmission of HIV and the importance of condom use, control of STD’s and client negotiation 
skills (20). More recently large scale efforts have been made in the country to educate all 
sexually active groups about HIV (20, 22). The National AIDS Control Plan III is India’s most 
recent response to their growing HIV epidemic (3). It will focus on scaling up investment on 
prevention activities among high risk populations, increasing antiretroviral treatment coverage 
and continued involvement and support of organizations and institutions in both public and 
private sectors.  Although a significant step in the right direction, many obstacles still remain due 
to cultural, legal and medical factors making HIV prevention and treatment in India a huge 
challenge (3, 19). 
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1.5.2 HIV-1 subtypes circulating in India 
Genetic analyses of HIV-1 circulating in different parts of India have shown that the 
predominant proportion of HIV-1 circulating in India is of subtype C origin with a small fraction 
made up of subtypes A and B (13, 23-28). Further genetic analysis has also shown that HIV-1 
subtype C from India shares homology to subtype C strains from Zambia and South Africa, 
however most C3 (Indian) strains were more closely related to each other than to subtype C from 
other countries (27, 29, 30). A recent study compared subtype C sequences from India to subtype 
C sequences sampled from Botswana, Burundi, South Africa, Tanzania, and Zimbabwe. Overall, 
HIV-1 type C sequences from different parts of India were more closely related to each other 
(10%) than to subtype C sequences from Botswana, Burundi, South Africa, Tanzania and 
Zimbabwe (15-21%) (13) (Figure 6). These results indicate that subtype C sequences in India are 
distinct from subtype C sequences sampled from other countries. Additionally, several studies 
suggest a recent introduction of HIV-1 subtype C and HIV-2 into India from a similar set of 
founder strains or ancestor viruses (29, 31, 32) implying a more rapid spread of HIV-1 subtype C 
throughout the country. 
  15
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Figure 6. Phylogenetic relationships among HIV-1 subtype C env sequences sampled from different 
countries.  
Neighbor joining analysis using 192 sequences encoding the V3-V4 region. The presence of CIN signature amino 
acids are indicated by colored circles. Clustering of select countries are indicated. Reprinted with permission from 
the American Society for Microbiology from Shankarappa, et al. 2001. Human immunodeficiency virus type 1 env 
sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India 
from other subtype C sequences. J Virol 75(21):10479-87.Copyright © 2001 American Society for Microbiology. 
All rights reserved. 
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 Reports of subtype A and B viruses in India date back to 1991 and 1994, respectively 
(28). Since then these subtypes have been reported at a much lower frequency than subtype C 
although they have been transmitted via the same primary routes, i.e. sexual contact and injection 
drug use (13, 33, 34). This taken together with the fact that HIV-1 isolated from different parts of 
India at different times are closely related (13, 35, 36) suggest that the preponderance of subtype 
C viruses over other subtypes is most probably not due to continual introductions of HIV-1 
subtype C into the country or to recent immigration or representative of a cluster of isolated 
individuals.  
Over the course of the HIV-1 epidemic in India, and regardless of geographical area, 
subtype C has consistently accounted for 90-95% of infections with subtypes A, B and others 
accounting for the remaining 5-10% (27, 28, 31, 37, 38). It is possible that the disproportionate 
distribution of HIV-1 subtypes in India may be due to one or a combination of factors including 
founder effect, replication fitness and transmission efficiency. 
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1.6 CONCEPTS IN VIRAL FITNESS 
This section introduces evolutionary and fitness theories, defines fitness as it relates to RNA 
viruses, describes assays used to measure fitness and describes in vitro replication fitness as it 
relates to this study.    
1.6.1 Concepts in Viral Fitness 
Distinctive features of RNA viruses such as HIV include high genetic variation as a result of 
mutations caused by error-prone replication machinery and a lack of repair and proofreading 
mechanisms, high yields of virions and short replication times (39, 40). Due to these unique 
traits, RNA viruses have frequently been used to test both evolutionary and fitness theories (39-
45). Among the principles tested with RNA viruses are the Red Queen hypothesis and the 
competitive exclusion principle (using vesicular stomatitis virus, VSV) and Muller’s ratchet 
(using VSV followed by foot-and-mouth-disease, FMDV). The Red Queen hypothesis states that 
viral quasispecies that are cocultured in the same environment tend to gain fitness with each viral 
passage, although one eventually overgrows the other (42). The competitive exclusion principle 
states that when two species coexist in the same environment with limited resources, one will 
always outgrow the other (40, 46, 47). Finally, changes in environment such as viral passage in 
tissue culture, plaque-to-plaque transfers or transmission events which alter or decrease 
population size, may create genetic bottlenecks which can decrease gains in fitness or cause an 
overall fitness loss. In such cases the Muller’s ratchet hypothesis states that decreases in average 
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fitness due to an irreversible gain of deleterious mutations in limited populations cannot be 
compensated for and will overwhelm the appearance of mutations improving fitness (40, 41, 46, 
47). Initially HIV was not used as a tool to test these fitness theories. However, more recently 
there have been increasing data using HIV variants in growth competition assays to study in vitro 
replication fitness dynamics. Although several implications have been made, the relationship 
between in vivo replication capacity (including disease progression, transmission and spread) 
and in vitro fitness remains unclear.  
1.6.2 Fitness: Definition and Influential Factors  
Fitness is an evolutionary term used to describe the ability of an organism to reproduce and adapt 
to its particular environment (39). For RNA viruses, fitness can be estimated by the relative 
ability to produce stable infectious progeny in a given environment (39). HIV fitness can be 
affected by any combination of host or viral factors. For example, the first obstacle encountered 
by the virus is upon sexual transmission in which a severe bottleneck selects for those variants 
that use the CCR5 coreceptor (11). This event reduces the population size from donor to 
recipient (48) resulting in a more homogeneous population with a narrower genetic distribution 
of quasispecies as compared to the donor (49). Thus, as stated for Mueller’s ratchet evolutionary 
theory, continued bottleneck events can result in an overall fitness loss to the viral population. 
Additional host factors affecting viral fitness include mutations or polymorphisms in the CCR5 
coreceptor that could affect transmission or disease progression in the host and selective pressure 
imposed by HIV-specific CTLs which could select for escape variants with reduced fitness (11). 
Viral factors affecting fitness include the high mutation rate of HIV which greatly contributes to 
the adaptability of the virus which can result in overall fitness gains (11). In addition, differences 
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in in vitro replication fitness have been shown to be due to efficiency of binding related to the 
gp120 region of the envelope gene. The nef gene is another viral factor that may influence fitness 
since it has been reported that some long term nonprogressors harbored HIV strains having nef 
deletions (50). 
1.6.3 Growth Competition Assays as a Tool to Measure Fitness 
Ex vivo fitness assays are valuable because they focus solely on replication efficiency and 
eliminate selective pressures by the human host on the infecting virus - which may vary from one 
host to another (47). These assays can discern small differences in fitness as opposed to side-by-
side growth kinetic assays that may only distinguish gross changes in replicative fitness (49). 
Furthermore, dual infection assays provide the internal control that cannot be ensured in separate 
monoinfections and relative fitness can be directly compared since one clone will eventually 
outgrow the other (39, 44, 47). Ex vivo (in vitro) fitness has been shown to correlate with disease 
progression and therefore can be a useful predictor of disease progression (51). 
1.6.4 Relationship Of in vitro Replication Fitness to HIV-1 Disease Progression and 
Global Distribution 
It is not fully understood how in vitro replication fitness and transmission efficiency relate to the 
in vivo situation or the current asymmetric distribution of HIV-1 subtypes globally, but as new 
data continues to support this hypothesis it further strengthens the idea that genetic variability 
within subtypes may be correlated with in vivo fitness and HIV population dynamics. The 
seminal study examining this issue came in 2000 where using an in vitro dual infection growth 
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competition assay, Quinones-Mateu and colleagues showed that there was a correlation between 
ex vivo (in vitro) fitness and disease progression. In this study, HIV-1 isolates from progressive 
patients were shown to be significantly more fit than HIV-1 isolates from long-term survivors – 
in several cases independent of viral phenotype. It was also shown that a subtype C primary 
isolate from Brazil was outcompeted and thus less fit than both a Rwandan subtype A primary 
isolate and a laboratory adapted subtype B strain (51). In a more recent study, the ex vivo fitness 
of CCR5-tropic HIV-1 isolates of subtypes B and C were compared by performing pair-wise 
competitions (52). All subtypes C isolates were outcompeted by subtype B isolates in all cell 
types except Langerhans cells. In these cells, subtype C demonstrated competitive replication 
efficiency against subtype B indicating that transmission between these two subtypes may be 
similar. These findings suggest that slower disease progression to AIDS (reduced viral fitness) 
coupled with efficient transmission may have contributed to the current subtype C global 
distribution.  
Recently, an order of relative fitness was assigned to HIV viruses: HIV-1 group M > 
HIV-2 >> HIV-1 group O (53). In this study in vitro growth competition assays were used as a 
tool to evaluate fitness differences among HIV groups and types and suggests that the lower 
replicative capacity of group O and HIV-2 compared to group M may have led to decreased 
transmission and distribution of these groups in the human population. In this scenario, a 
drastically lower replicative capacity may be impairing transmission of the virus due to low viral 
loads, resulting in reduced spread of the less fit variant. Another recent study found that 
CRF02_AG isolates had higher in vitro replication capacities in PBMCs than subtype A and G 
viruses from the same geographic region. The higher fitness was independent of coreceptor 
tropism and irrespective of high or low CD4+ T cell counts (54, 55). Over the last 10 years 
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CRF02_AG has become the predominant subtype in West and West Central Africa. While this 
current state may be due to founder effect, these findings along with others previously mentioned 
suggest that altered replicative capacity acquired by intersubtype recombination events could 
have contributed to the disproportionate spread of CRF02_AG.  
However, since heterosexual transmission in India is more closely related to subtype C 
viruses, it is possible that HIV-1 subtype C viruses may posses enhanced fitness properties ideal 
for mucosal entry and establishment of infection as compared to other subtypes present in India. 
This argument is further supported by the fact that the length of time to progression to AIDS 
appears to be shortest in women infected with subtype C as compared to those infected with 
subtype A, D or G (56). In fact, women infected with subtype C appear to be 15 times more 
likely to develop AIDS than those infected with subtype A (56, 57) and women infected with 
subtype C virus have been associated with increased vaginal shedding compared to infection 
with subtypes A or D (58). 
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1.7 SEXUAL TRANSMISSION OF HIV-1 
This section describes the mechanisms by which HIV-1 is heterosexually transmitted and 
describes relevant findings on the relationship between HIV-1 subtypes and sexual transmission. 
1.7.1 Sexual Transmission of HIV-1 
Heterosexual intercourse is the primary route of HIV-1 transmission and accounts for 80% of 
new infections worldwide (59). According to the UNAIDS 2006 report, 17.7 million women are 
infected with HIV. This accounts for nearly half of infected individuals living with HIV. The 
majority of these women live in Sub-Saharan Africa and Asia where the epidemic is rampant. 
The probability of transmission for each heterosexual encounter is low (about 0.001) and is 
related to dose, i.e. the amount of virus present in genital fluids (60-62) and disease stage (2). 
Strains that use the CCR5 coreceptor are preferentially transmitted over strains that use CXCR4. 
This is likely due to the host induced bottleneck in which epithelial cells selectively captures and 
transfers R5 viruses (61, 63). This is supported by the fact that individuals that posses a deletion 
in CCR5 are generally resistant to infection (64, 65) and those that contain a mutation in the 
CCR5 allele progress to AIDS more slowly than those that have wild type CCR5. 
    In vivo, the lower female genital tract is comprised of different anatomical regions including 
the vaginal mucosa, the ectocervix and the endocervix (66). The ectocervix and vaginal mucosa 
contain several layers of non-keratinized stratified squamous epithelial cells forming a barrier to 
block infection. The squamocolumnar junction or cervical transformation zone is the region in 
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which the multilayered ectocervix transitions to a single layer of columnar epithelium that is the 
endocervix (62, 66). The topology of the endocervix likely makes it more vulnerable to HIV-1 
infection (67). The target cells for HIV virus in the underlying cervicovaginal submucosa are 
‘resting’ and activated CD4+ T cells, macrophages and dendritic cells (68) (Figure 7). It is still 
unclear how HIV manages to infiltrate an intact mucosal surface since when intact, the epithelial 
layer should serve as a suitable barrier to block infection due to vaginal mucus, which can trap 
and dilute virus; low pH and antimicrobial peptides like cytokines and chemokines, which can 
block infection (69). However STD’s, inflammation or trauma or microscopic breaks in the 
epithelial surface could allow entry of the virus and exposure of susceptible cells in the 
submucosa. There are four potential mechanisms by which HIV can penetrate the mucosal 
surface: 1) transcytosis through epithelial cells or specialized M cells; 2) epithelial 
transmigration of infected donor cells; 3) association with dendritic cells that can both capture 
virus in the lumen via C-type lectins (61) or themselves become infected and transfer the virus to 
susceptible cells in the lamina propia and lymph nodes; and 4) through physical breaks in the 
epithelial barrier (2, 61, 62) (Figure 7). 
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 Figure 7. Potential mechanisms for HIV-1 transmission across the mucosal epithelium 
a) Direct infection of epithelial cells. b) Transcytosis through epithelial cells and or M cells. c) Epithelial 
transmigration of infected donor cells. d) Uptake by intraepithelial Langerhans cells. e) Crossing of the epithelial 
barrier through physical abrasions. Reprinted by permission from Macmillan Publishers Ltd. Nat Rev Microbiol. 
Shattock RJ and Moore JP. Inhibiting sexual transmission of HIV-1 infection. 2003;1(1):25-34, copyright 2003. 
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 Once the virus has successfully penetrated the mucosal epithelial barrier, it now has 
access to underlying susceptible cells. Using a modified organ culture system, Hladik et al. (70) 
observed that intraepithelial memory T cells expressing CD4 and CCR5 became infected within 
two hours of virus exposure. HIV was also found associated with Langerhans cells, however no 
interaction was observed at this early timepoint between LCs and T cells. This suggests that HIV 
infection of T cells is not dependent on LC-mediated viral uptake or enhancement of infection in 
trans (70, 71). Upon emigration from the epithelium several interactions between LCs, T cells 
and DC’s have been suggested for the propagation of infection. First, LCs may be involved in 
transfer of virus to T cells across an “infectious synapse”. Second, LCs could transfer virus to 
DC’s in the stroma and finally, stromal DC’s could acquire virus from infected T cells (71). 
Using a cervical tissue derived organ culture, our laboratory has shown that activated memory 
CD4+T cells are the first cell types that become infected within 6 hours of infection. Infection of 
macrophages and DCs were detected 24-96 hr after infection (72). 
Using a rhesus macaque simian immunodeficiency virus (SIV) model, Miller et al. (73) 
observed that in the first three days post-intravaginal infection there was limited penetration of 
the mucosal barrier despite having used very high titer virus inoculum. They also observed that 
within these first 72 hours, the infection was confined to a small focus of founder populations of 
infected cells and that there was rapid dissemination to distal sites from this portal of entry. 
These founder populations served as a continuous source of virus from which distal sites and 
lymphatic tissue compartments could establish productive infection. Productive systemic 
infection was observed within six to ten days post infection. These studies using ex vivo organ 
cultures and the rhesus macaque model have been instrumental in our understanding of target 
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cells involved in HIV transmission and the extent and timing of HIV-1 infection and 
dissemination. Furthermore, we can draw relevant conclusions from the macaque model since 
target cells, physiology and immunology of the macaque female genital tract have all been 
shown to be similar to humans (73). 
1.7.2  Role of Subtypes in HIV- Transmission 
The association between HIV subtype and mode and efficiency of transmission has been under 
investigation since early on in the global HIV epidemic. Some studies have reported an 
association between subtype B and homosexual practices (74, 75). Whereas subtype E was 
identified in the majority of cases where there was heterosexual contact (76). Additionally a 
South African study found a highly significant correlation between subtypes B and C in 
homosexual and heterosexual contacts, respectively (75). The majority of infections by HIV are 
through heterosexual intercourse. The subtypes of HIV-1 that appear to spread most successfully 
by heterosexual transmission may have biologic features that contribute to efficient heterosexual 
transmission. Recently an order of relative fitness was assigned to HIV viruses based on in vitro 
growth competition assays in PBMC and a dendritic cell – T-cell transmission model system 
(77). The order (group M > HIV-2 >> group O) is consistent with the current global subtype 
distribution and suggests a correlation between in vitro and in vivo fitness, replication capacity 
and transmission. 
There is still debate over which cells are the initial targets of HIV upon heterosexual 
exposure. Langerhans cells (52, 78-80), dendritic cells (81), macrophages (82) and activated 
CD4+ T-cells (70, 72, 83) have all been implicated. Nevertheless, Langerhans cells have been 
the primary cell used in HIV-1 transmission model systems. Langerhans cells are immature 
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phagocytic dendritic cells found under most surface pluristratified epithelia such as the female 
cervix and vagina (84). These cells have been proposed to be primary target cells following 
sexual exposure to HIV (52, 74, 78, 79). Recent studies have shown that although it is 
outcompeted by other subtypes in PBMC, subtype C competes efficiently in Langerhans cells 
(52, 77). Soto-Ramirez et al. (74) reported that HIV-1 subtypes E and C strains from Thai and 
Indian heterosexuals, respectively, replicated in Langerhans cells more efficiently than subtype B 
strains from US homosexual men (74). Therefore Langerhans cells in the foreskin of the penis 
and the cervicovaginal epithelium could be very important for transmission and dissemination 
during sexual transmission of HIV-1. Recently primary Langerhans cells isolated from cervical 
tissues were shown to be refractory to HIV-1 infection by way of Langerin which may act as a 
natural barrier to HIV-1 infection (166). More studies are necessary to determine the role of 
Langerhans cells in HIV-1 infection and to determine the degree of subtype-specific replication 
in these cells. The efficiency of replication in Langerhans cells may imply more efficient 
transmission across the epithelial surface. Subtype-specific replication efficiency differences in 
Langerhans cells could result in subtype-specific differences in transmission efficiency and 
dissemination throughout a population. 
1.7.3 Models for the Study of HIV-1 Transmission 
The development of model systems to study HIV-1 transmission has been very useful to 
investigate the early molecular and cellular events involved in this process. For example, primary 
and transformed genital epithelial cells have been used to investigate viral (85) and cellular (66) 
transmigration, respectively. To identify initial targets of HIV-1 infection, tissue sections and 
isolated cell cultures (86), epidermal sheets (87) and ex vivo organ culture models (70, 88-90) 
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have been used. A more comprehensive picture of the virological and immunological events 
surrounding HIV-1 transmission has been given by the animal model. Rhesus macaques can 
efficiently transmit SIV or SIV/HIV chimeras by vaginal inoculation and endure a natural course 
of infection similar to what is observed in humans.  Using animals, investigators have been able 
to examine early and late events after intravaginal exposure and better understand viral 
propagation and systemic dissemination (59, 91). While animal models hold the most promise, 
they are generally expensive to use on a routine basis and could potentially yield misleading 
information regarding heterosexual transmission of HIV-1 in humans (92).  
As discussed in section 1.7.2, a limited number of studies have investigated the 
differences in replication fitness or transmission efficiency of HIV-1 subtypes in cells from the 
vaginal mucosa. This study is novel in that it uses tissues rather than a monolayer of cells to 
determine replication fitness differences. Our ex vivo organ culture model most closely 
represents the in vivo situation in humans since it provides the natural tissue architecture of the 
female genital organ, including epithelial cells, submucosa and immune cells, such as T cells, 
macrophages and Langerhans cells (88).  
1.8 ROLE OF LTR AND ENVELOPE GENE IN HIV-1 REPLICATION FITNESS 
The long terminal repeat (LTR) of HIV regulates the expression of the viral genome through its 
interaction with both cellular and viral transcription factors (93). The HIV-1 LTR is 
approximately 640 base pairs long and is divided into three structural regions designated, U3, R 
and U5 (Figure 8). The U3 region is further subdivided into the modulatory, enhancer and 
core/promoter functional regions (93, 94). The U3 region is of particular interest because it 
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contains binding sites for several key transcription factors such as NF-κB, Sp-1, NF-AT, USF 
and TCF1-α, which regulate HIV transcription (94, 95).  
R U5
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NFAT NFAT USFGATA-3 TCF1-αAP-1 NF-κB Sp-1 TATA TAR
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core
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Figure 8. Schematic diagram of the structure of the HIV-1 LTR. 
The binding sites for select cellular transcription factors are shown. The transcription start site (+1) is indicated.  
 
 
There is a growing body of data indicating subtype specific differences of the HIV-1 LTR 
at both the molecular and functional levels (95-99). Comparisons of HIV-1 subtypes show 
differences in the number and organization of transcription factor binding sites within the 
promoter region (100). The subtype C LTR in particular has been shown to contain three NF-κB 
binding sites instead of two that are carried by the majority of subtypes (101-103). This 
additional NF-κB enhancer site in subtype C has been correlated with increased promoter 
activity and increased viral replication (96, 98, 104, 105). A study by van Opijnen et al. , showed 
that differences in viral replication and fitness rates were determined by the HIV-1 subtype-
specific LTR and was dependent on both the host cell type and activation status of the cell (98). 
In another study by Centlivre et al., Chinese rhesus macaques were co-infected with subtype B, 
C and E short terminal repeat cloned virus which consisted of the HIV-1 subtype-specific LTR 
core promoter/enhancer region in a neutral SIVmac239 backbone. This study showed that viral 
replication was HIV-1 LTR subtype-dependent and suggests that subtype C is particularly 
adapted to sustain viral replication in primary viremia. This conclusion was based on the 
observation that there was a strong predominance of the subtype C chimera during primary 
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infection followed by the dominance of subtype B in all tissues later in infection. Taken together 
these data suggest that HIV-1 LTR subtype variability may influence virus replication in a host 
cell specific manner and at different stages of disease. Therefore the higher replicative fitness of 
HIV-1 subtype C early in infection may generate higher viral loads during the asymptomatic 
period compared to other subtypes which could promote viral transmission. It is therefore 
relevant to investigate whether these same conclusions can be made regarding HIV-1 subtype C 
in India. This may help to explain the predominance of this subtype in India today and 
throughout the HIV epidemic.  
The envelope gene (env) of HIV-1 is responsible for viral infectivity, co-receptor usage, 
and pathogenesis (in vitro). For example, changes in amino acids within the V3 loop of gp120   
are correlated with coreceptor usage and disease progression. Basic amino acids at positions 11 
and 25 in the V3 region are correlated with CXCR4 coreceptor usage, rapid disease progression 
and syncytium formation in vitro. Viruses with this genotype usually emerge late in the 
chronic/symptomatic stage of disease and correspond with a rapid decline in CD4+ T cells and 
progression to AIDS. Whereas an absence of basic amino acids at these same positions, are 
correlated with CCR5 coreceptor usage and slow disease progression. Viruses of this genotype 
are principally found after initial infection and in the asymptomatic phase of disease.  
High mutation frequency caused by the viral reverse transcriptase coupled with selective 
pressures of the host environment have caused the envelope gene to exhibit the highest 
variability (5-25% nucleotide diversity) within the  genome among HIV-1 subtypes. Considering 
the important functions of env together with its high sequence diversity has led investigators to 
speculate that this gene may be one of the factors involved in determining replication capacity 
and fitness of the virus. Several studies have proposed that viral entry mediated by env is the 
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major determinant of fitness (52, 106, 107). Rangel et al. (106), and Marozsan et al. (107), both 
used chimeric env viruses to show that HIV-1 fitness was env dependent. Furthermore, Ball et al. 
showed that in dual competition experiments between HIV-1 isolates of different subtypes, the 
more fit variant was determined within 8-24 hours and this observed difference in fitness 
occurred at the level of entry rather than other steps in the retroviral life cycle such as reverse 
transcription, integration or viral mRNA transcription. Based on these findings, Marozsan et al, 
(107) extended these studies and determined that the ability of one isolate to outcompete another 
was due to the efficiency of host cell entry (specifically binding and fusion) mediated by the 
gp120 coding region of env. These data suggest that HIV-1 subtype fitness differences occur at 
the level of viral entry and are due to diversity within the envelope gene.  
Therefore Indian subtype C may be more replication fit than Indian subtype A due to 
subtype specific variability within the LTR or to a higher rate of infectivity mediated by env. 
This fitness advantage of subtype C over subtype A may help to explain the asymmetric 
distribution of subtypes of HIV-1 in India. 
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
Rationale 
The dominance and disproportionate spread of HIV-1 subtype C compared to other subtypes in 
India suggests that subtype C may possess a biological growth advantage making it more 
replication efficient and/or more efficiently transmitted across the mucosal surface. Ex vivo 
fitness assays are valuable tools for exploring such biological differences because they focus 
solely on replication efficiency and eliminate selective pressures by the human host on the 
infecting virus-which may vary from one host to another (47). Furthermore, ex vivo fitness has 
been shown to correlate with disease progression and thus be a useful predictor of disease 
progression (51). There is a growing amount of data which suggest that fitness differences 
among HIV-1 subtypes are dependent on the envelope gene. Chimeric constructs of HIV-1 
subtype envelope genes in neutral backbones have demonstrated differences in replicative 
capacity, fusion and competitive binding, all of which were shown to be dependent on env. The 
LTR of HIV-1 has also been proposed as the region responsible for determining differences in 
subtype fitness. Studies have reported that variations in LTR transcription factor binding (TFBS) 
sites among HIV-1 subtypes resulted in altered transcription efficiency in the presence and 
absence of stimuli and in different cell types. 
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Hypothesis 
The asymmetric distribution of HIV-1 subtype C in India is due to enhanced replication fitness 
and/or enhanced transmission efficiency of this subtype over other subtypes present in India.  
 
 
Specific Aims 
The overall objective of this proposal is to elucidate the mechanism of asymmetric distribution of 
HIV-1 subtypes in India. Specific aims of this study are:  
 
1) To construct and characterize an infectious molecular clone of HIV-1 subtype 
A of Indian origin. 
2) To evaluate the replication fitness of HIV-1 subtypes A and C from India using 
an in vitro growth competition assay 
3) To compare the transmission efficiency of HIV-1 subtypes A and C from India 
across the mucosa of cervicovaginal tissue. 
4)  To evaluate the roles of the LTR and env in replication fitness and 
transmission efficiency across cervicovaginal tissue. 
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3.0  CHAPTER ONE.  CONSTRUCTION AND CHARACTERIZATION OF AN 
INFECTIOUS MOLECULAR CLONE OF HIV-1 SUBTYPE A OF INDIAN ORIGIN 
3.1 PREFACE 
This chapter is adapted from a published study (Milka A. Rodrigueza , Yue Chena , Jodi K. 
Craigob, Ramdas Chatterjeec , Deena Ratnera , Masashi Tatsumid , Pratima Roye , Dhruba Neogie  
and Phalguni Guptaa. 2005. Virology. 345:328-336.). Work described in this chapter is in 
fulfillment of specific aim 1.  
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3.2 ABSTRACT 
India has the second highest number of HIV-1 infected people next to South Africa. The 
predominant proportion of HIV-1 circulating in India is of subtype C origin, with a small fraction 
made up of subtypes A and B. In this report, we describe the construction and characterization of 
the first full length infectious molecular clone p1579A-1 HIV-1, from an HIV-1 subtype A 
infected person from India, using long PCR and successive ligation of the amplimers. 
Phylogenetic analysis of the sequence of the entire proviral DNA and LTR confirmed p1579A to 
be an HIV-1 subtype A. Analysis of the envelope gene of p1579A-1 showed a conserved GPGQ 
motif and the absence of basic amino acids at positions 11 and 25 suggesting CCR5 co-receptor 
usage. Analysis of env N-linked glycosylation sites revealed fewer sites in the V1 region of 
envelope compared to other subtype A. Transcription factor binding site analysis of the LTR 
sequences identified conserved as well as unique transcription factor binding sites (TFBS) in 
p1579A-1. This infectious clone of HIV-1 can be useful to study the molecular mechanism of 
dominance of subtype C in India. 
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3.3 INTRODUCTION 
HIV-1 was first reported in Tamil Nadu, India in 1986 among female commercial sex workers 
(108, 109). Since then, HIV-1 has spread rapidly throughout the country and has been reported in 
nearly every major city. Today, India has the second largest number of HIV-1 infected 
individuals in the world next to South Africa (3). Genetic analyses of HIV-1 sequences 
circulating in different parts of India have shown that the predominant proportion of HIV-1 
circulating in India is of subtype C origin with a small fraction of subtypes A and B (13, 23-28). 
Furthermore, phenotypic and genotypic analysis of env sequences of HIV-1 in India indicate that 
they are CCR5 tropic with non-syncytium inducing phenotype even when they are isolated from 
late stage of infection (110). We have recently analyzed subtype C sequences from India and 
then compared this set of sequences to subtype C sequences sampled from Botswana, Burundi, 
South Africa, Tanzania, and Zimbabwe. Overall, HIV-1 type C sequences from different parts of 
India were more closely related to each other (10%) than to subtype C sequences from Botswana, 
Burundi, South Africa, Tanzania and Zimbabwe (15-21%) (13). These results indicate that 
subtype C sequences in India are distinct from subtype C sequences sampled from other 
countries.  
Over the course of the HIV-1 epidemic in India, and regardless of geographical area, 
subtype C has consistently accounted for 90-95% of infections with subtypes A, B and others 
accounting for the remaining 5-10% (27, 28, 31, 37, 38). This together with the fact HIV-1 
isolated at different parts of India at different times are closely related (13) suggests that, the 
preponderance of subtype C viruses over other subtypes is most probably not due to  new and 
continual introductions of HIV-1 subtype C into the country or  to  recent immigration or 
  37
representative of a cluster of isolated individuals.  It is possible that the disproportionate 
distribution of HIV-1 subtypes in India may be due to one or a combination of factors including 
founder effect, replication fitness and transmission efficiency. In order to elucidate the molecular 
dynamics of HIV-1 subtype distribution in India it is important to have an infectious molecular 
clone, such as subtype A, from India. Reports of subtype A viruses in India date back to 1991 
(28) and since then they have been periodically reported in various studies (13, 33, 34). To date 
there are no sequence data of the complete genome of an HIV-1 subtype A nor does a replication 
competent infectious molecular clone of subtype A exist. Here we report the construction of a 
full-length infectious molecular clone of subtype A HIV-1 from India and delineation of its 
complete genomic sequence. 
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3.4 MATERIALS AND METHODS 
3.4.1 Virus Cultures 
PBMC from 19 HIV-1 positive Indian patients were cultured in the presence of  
phytohemagglutin (PHA)-stimulated, CD8-depleted normal donor PBMC in RPMI 1640 media 
supplemented with IL-2 as described previously (111, 112). Production of virus was monitored 
by HIV-1 p24 production in the culture supernatant. Virus was harvested every 5 days for 40 
days. 10-20 million cultured cells were pelleted and stored at -80°C for DNA isolation and 
subtyping.  
 
3.4.2 DNA Isolation and HIV-1 Env Subtyping by HMA 
High molecular weight chromosomal DNA was purified from cultured cell pellets using 
PUREGENE DNA purification kit. The DNA was then subjected to a heteroduplex mobility 
assay (HMA), as described previously (31). ED5/ED12 primers were used to PCR amplify the 
V1-V5 region of the envelope gene followed by a nested PCR amplification of the C2-V5 region 
using primers DR7/DR8. The cycling conditions for both primer pairs were as follows:  3 cycles 
of 94°C for 1 minute, 55°C for 1 minute, 72°C for 1 minute. Followed by 32 cycles of 94°C for 
15 seconds, 55°C for 45 seconds, 72°C for 1 minute. Final extension at 72°C for 5 minutes.  
DR7/DR8 PCR products from each of the reference plasmids and the unknown HIV-1 were then 
combined, denatured at 99°C for 5 minutes and then reannealed on wet ice for 10 minutes. 
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Heteroduplexes were resolved on a 5% nondenaturing polyacrylamide gel at 250V for 3 hours. 
The gel was then stained with ethidium bromide and visualized in a phosphoimager.  
 
3.4.3 Construction of the Full Length Infectious Molecular Clone 
The entire 1579A genome was amplified in three fragments. Long PCR was performed using the 
high fidelity AccuPrime Pfx DNA polymerase (Invitrogen) and 1ug of chromosomal DNA from 
HIV-1 1579A infected cells. Three overlapping sub-genomic fragments of 2.5kb, 5’LTR-gag, 
6.2kb, gag-env, and 2.7kb, env-LTR3’, were generated using PCR primers shown in Table 1. 
The cycling conditions were as follows: 1 cycle of 95°C for 2 minutes. Followed by 10 cycles of 
94°C for 10 seconds, 55°C for 30 seconds and 66°C for 2 minutes. Followed by 25 cycles of 
94°C for 15 seconds, 55°C for 30 seconds and 66°C for 2 minutes. Final extension at 66°C for 7 
minutes. Extension times were increased by 5 seconds every additional cycle. Annealing 
temperatures for 2.5kb, 6.2kb and 2.7kb were 50°C, 55°C and 57°C, respectively. PCR products 
were gel purified using Mo Bio Laboratories DNA purification kit and then cloned into pCR-
Blunt II TOPO vectors (Invitrogen) resulting in plasmids A, B and C, respectively. The plasmid 
A carrying the 2.5kb HIV-1 DNA fragment and the plasmid B carrying the 6.2kb HIV-1 DNA 
fragment was digested with unique restriction enzymes. The 4.4kb fragment from the plasmid A 
was ligated to the 6.7kb fragment from the plasmid B to generate a plasmid D that contained a 
7.6kb fragment encompassing the 5’LTR-env region of the 1579A HIV-1 genome. The plasmid 
C carrying the 2.7kb HIV-1 DNA fragment and plasmid D were then digested with unique 
restriction enzymes. The 9.6kb fragment from the plasmid D was ligated to the 3.9kb fragment 
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from the plasmid C to generate a plasmid that contained the complete full length HIV-1 proviral 
genome of 1579A and was designated p1579A. 
 
 
Fragment Length Position Primer Sequence (5’Æ 3’) 
U3XhoI ATT ACT CGA GTG GAT GGG TTA ATT 2.5kb 5’LTR-pol 
HIV-1Pol1 ACT GGT ACA GTC TCA ATA GGA CTA ATT G 
SK145 AGT GGG GGG ACA TCA AGC AGC CAT GCA AAT6.2kb gag-env 
DR8 GGG ACA ATT GGA GAA GTG 
DR7 CAA CTG CTG TTA AAT GGC AGT CTA GC 2.7kb env-3’LTR 
 New LTR 3’ NotI ATA AGC GGC CGC CCA CTG CTA GAG ATT T 
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Table 1. Primers Used for Amplification of HIV-1 Subtype A Genome 
 3.4.4 Transfection, replication kinetics, co-receptor usage and MT2 Assay 
HEK293T cells (ATCC) were maintained in DMEM supplemented with 15% FBS, 1% L-
glutamine, 1% penicillin-streptomycin, 1ug/ml puromycin and 300ug/ml G418. 293T cells that 
were grown to 90-95% confluency were transfected with 14ug of p1579A-1 DNA or 35ug of 
control plasmid pIndie C1 with Lipofectamine 2000 reagent (Invitrogen). Transfected HEK293T 
cells were cultured in 15% D-MEM media for 48hrs. After 48hrs, supernatant from transfection 
cultures was passed through a 0.45micron filter and added to 5 million PHA stimulated CD8 
depleted PBMC treated with 5ug/ml polybrene for 1 hour in RPMI media supplemented with IL-
2. Cultures were maintained at 37°C. Cultures were tested for the presence of p24 antigen every 
2-3 days and fed with 2.5 million PHA stimulated and polybrene treated CD8 depleted PBMC 
every 7 days.  
To determine the co-receptor usage of p1579A-1 virus U87.CD4 cells were infected as 
described (113). Briefly, U87.CD4 cells expressing either the CXCR4 or CCR5 chemokine 
receptors were seeded in duplicate in a 24-well microtiter plate at a concentration of 250,000 
cells/well in a final volume of 500ul 15%D-MEM. The cells were incubated at 37°C until they 
became 90% confluent. The media was removed from confluent cells and the cell monolayer was 
washed with 500ul PBS. Approximately 0.5 ml (30 pg p24 equivalent) of p1579A-1 or the 
control HIV-1 BAL or IIIB was added to duplicate wells of U87.CD4.CCR5 and CXCR4 cells. 
One set of wells for each co-receptor was left uninfected as a negative control. An additional 0.5 
ml of DMEM containing 15% FCS was added to each plate and the plates were incubated at 
37°C for 24hrs. After 24hrs, the supernatant was removed. The cells were rinsed with PBS and 
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incubated in 1 ml fresh DMEM supplemented with 15% FCS. HIV-1 p24 production in the 
supernatant was monitored every 2 days.  
To determine the replication kinetics of p1579A-1 cloned virus 10 million PHA-
stimulated CD8 depleted PBMC treated with 5ug/ml polybrene for 1 hour, were infected with 
approximately 30ng equivalent HIV-1 p24 virus of either cloned virus or the parental isolate. 
The infections were carried out for 2 hours, with shaking every 30 minutes at 37°C. After the 2 
hours, the virus supernatant was removed and the cells were washed and cultured at 37°C in 
RPMI 1640 medium containing 20% FCS and 5% IL-2. Virus growth was monitored every 2 
days by p24 antigen production in the culture supernatant.  
MT2 assay to measure syncytia inducing activity of HIV-1 was performed as described 
previously (114). 
 
3.4.5 Sequencing, phylogenetic analysis and molecular characterization 
The entire viral genome was sequenced using an automated sequencer. Sequences were manually 
joined and contiguous sequence fragments were assembled using the Vector NTI suite software 
program (Informax, Oxford, UK). DNA and protein alignments were constructed using the 
CLUSTAL X alignment program of Vector NTI.  Consensus sequences and subtype reference 
sequences used for alignments were obtained from the Los Alamos HIV-1 database.  
 Phylogenetic analyses of the entire genome sequence was constructed by the neighbor-
joining method of Jukes Cantor corrected distances (protein, total mean character corrected 
distances) with the optimality criterion set to distance as measured in PAUP. Statistical 
significance of branchings and various clustering were assessed by bootstrap re-sampling of 
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1000 pseudoreplicates on the complete data set. The trees were edited for publication using 
Treeview68K version 1.5. Phylogenetic analyses of LTR sequences were conducted through the 
construction of maximum-likelihood trees as measured in PAUP. Statistical significance of 
branchings and various clustering were assessed by bootstrap re-sampling of 1000 
pseudoreplicates on the complete data set.   The trees were edited for publication using 
Treeview68K version 1.5.  
 N-glycosylation site analysis was performed at the Los Alamos HIV-1 database. 
Transcription factor binding site predictions were performed using MatInspector. 
GenBank Accession Number:  DQ083238 
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3.5 RESULTS 
3.5.1 DNA isolation and subtype determination 
From the molecular epidemiological data it is expected that very few subjects will be infected 
with subtype A HIV-1. Therefore, we have performed virus isolation from a number of HIV-1 
infected subjects and determined their subtype specificity.  The infected subjects for this study 
were recruited from Calcutta, the major eastern city of India. A summary of patient 
characteristics is shown in Table 1.  
 
 
Table 2. Characteristics of HIV-1 infected subjects from India 
Patient 
ID# Age Sex Clinical Symptoms CD4 Count  Subtype  
      
2145 33 F NAD 678/ul C 
1577 18 F NAD 814 C 
2161 53 M asymptomatic 427 C 
1590 16 F weakness, anorexia 736 C 
2024 25 F NAD 350 C 
1310 25 F abdomen pain, diarrhea 343 C 
1581 21 F fever, cough, weakness 377 C 
1580 18 F NAD 810 C 
1540 20 F 
total body pain, menstrual 
problems 640 C 
1579 16 F Sore throat, weight loss 477 A 
1443 34 F weakness 702 C 
2167 25 F abdomen pain, leucorrhoea 255 C 
1585 21 F weakness 331 C 
2163 25 F weakness, anorexia 275 C 
2177 18 F cold & cough, weakness 193 C 
NAD – nothing abnormal detected 
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HIV-1 was isolated from these patients by coculturing their PBMC with PHA-stimulated CD8 
depleted normal donor PBMC as described previously (111, 112). Production of virus was 
monitored by HIV-1 p24 production in the culture supernatant. Following thirty to forty days of 
cultivation, chromosomal DNA was extracted from the infected cell pellets. The DNA was then 
used to determine the subtypes of HIV-1 isolates using a heteroduplex mobility assay (HMA) kit 
obtained through the NIH AIDS Repository (31, 93, 115). In this assay, a nested PCR reaction 
was employed which in the first round amplified a ~1.25kb long amplimer encompassing the 
V1-V5 region of the HIV-1 envelope gene from proviral DNA. The 1.25kb DNA was then used 
as a template in the second round of PCR to amplify a ~0.7kb C2-V5 envelope gene fragment. 
Similar nested PCR primer pairs were also used for amplification of the C2-V5 region from 
reference plasmids carrying HIV-1 subtype A, B and C env sequences.  Nested PCR products 
from each of the reference plasmids and the unknown were then combined, denatured and 
reannealed. Subtypes were assigned based on the mobility of heteroduplexes on a nondenaturing 
polyacrylamide gel. Among the 19 HIV-1 positive Indian isolates tested, one, 1579, was found to 
be a subtype A (Table 1). Subtypes were further verified by sequencing the 0.7kb PCR products 
followed by its blast analysis at the Los Alamos HIV-1 Database (data not shown). Proviral 
DNA from this isolate (1579A) was then used to construct the subtype A infectious molecular 
clone.  
3.5.2 Construction of subtype A infectious molecular clone  
To construct the full length molecular clone, long PCR was performed using a high fidelity 
polymerase and chromosomal DNA from HIV-1 1579A infected cells. Three overlapping sub-
genomic fragments of 2.5kb: 5’LTR-pol, 6.2kb: gag-env, and 2.7kb: env-3’LTR were generated. 
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These three fragments were cloned into pCR-Blunt II-Topo cloning vectors (Invitrogen) 
resulting in plasmids A, B and C, respectively (Figure 9). Plasmids A and B were digested with 
unique restriction enzymes AhdI and FseI and the resulting fragments were ligated  to generate 
plasmid D containing a 7.6kb fragment of 1579A genome. Plasmids C and D were then digested 
with unique restriction enzymes DraIII and SnaBI and the resulting fragments were ligated to 
generate the full length infectious molecular clone, p1579A. Our cloning strategy exploited the 
pUC origin of replication and kanamycin resistance gene within the cloning vector such that the 
fragments being ligated together contained either one or the other of these features. This 
technique significantly lowered the background of our ligation products and facilitated cloning of 
these large fragments. 
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Figure 9. Construction of an HIV-1 subtype A infectious molecular clone.  
(A) PCR and cloning of three overlapping subgenomic fragments of 1579A genome. (B) Cloning strategy. Each of the plasmids was cut with unique restriction 
enzymes and the products ligated together to recover a complete full-length clone of 1579A. 
 3.5.3 Validation of molecular clone  
To validate the presence of the entire HIV-1 genome in p1579A clones, PCR was 
performed on three separate clones using gag, pol and env gene specific primers. Each of the 
three clones produced amplimers of correct size, 0.9kb, 1kb, and 0.7kb, corresponding to HIV-1 
gag, pol and env genes, respectively (Figure 10A). The intactness of these three clones gained 
further support by the analysis of the digestion pattern with NotI restriction enzyme which 
cleaves outside of the HIV-1 subtype A genome on either side. An approximate 10kb band 
corresponding to full length HIV-1 DNA and a 3.8kb band corresponding to the plasmid vector 
was observed for each clone that was digested (Figure 10B). One of these three clones, p1579A-
1, was used in subsequent biologic and genetic studies.  
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Figure 10. Validation of 1579A whole genome clone 
A) Validation of whole genome clone using HIV-1 PCR primers for gag, pol and env genes. M=marker. Lanes 1, 2, 
3; gag, pol, env (respectively) PCR products for clone #1. Lanes 4, 5, 6; gag, pol, env (respectively) PCR products 
for clone #2. Lanes 7, 8, 9; gag, pol, env (respectively) PCR products for clone #3. Lanes 10, 11, 12; gag, pol, env 
(respectively) PCR products for positive control of chromosomal DNA from 1579-infected PBMC. B) NotI 
restriction digest of whole genome clones. Schematic indicates NotI positions in plasmid. Gel image indicates 1579 
full length genome (~10kb) and plasmid vector (3.8kb). M=marker, Lanes 1, 2, 3 correspond to clones #1, #2 and 
#3.  
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 3.5.4 Infectivity of p1579A-1 
The infectivity of p1579A-1 was examined by transfection of human endothelial kidney (HEK) 
293T cells. Forty eight hours after transfection, filtered culture supernatant was used to infect 
CD8-depleted PBMC (116). Virus growth was monitored by measuring HIV-1 p24 antigen in 
culture supernatant. An infectious molecular clone of HIV-1 subtype C of Indian origin, 
pIndieC1, (117) was used as a positive control for transfection. Results shown in Figure 11A 
indicate that p1579A-1 is able to produce replication competent HIV-1. 
3.5.5 Molecular characterization of p1579A-1  
To characterize the growth properties of HIV-1 p1579A-1, CD8 depleted PBMC were infected 
with p1579A-1 virus (equivalent to 21ng of p24) collected from transfected culture supernatant 
and an equivalent p24 value of the parental HIV-1 subtype A isolate. Kinetics of viral replication 
was determined by measuring HIV-1 p24 antigen in culture supernatant. Figure 11B shows that 
p1579A-1 cloned virus has similar growth properties as the parental isolate. However, the 
parental isolate produced slightly higher p24 values than p1579A-1.    
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Figure 11. Transfection–infection of p1579A-1 DNA.  
(A) HEK293T cells were first transfected with p1579A-1 or the control pIndieC1 DNA. Two days after transfection, 
culture supernatant was then used to infect CD8 depleted PBMC. Production of HIV-1 p24 antigen on each day 
sampled is shown for p1579A-1 and the control pIndieC1. (B) Replication kinetics of p1579A-1. CD8 depleted 
PBMC were infected with 21ng of HIV-1 p24 equivalent virus supernatant of p1579A-1 or the parental isolate, 
1579A. Virus growth was monitored by measuring HIV-1 p24 antigen in the culture supernatant every 2 days. 
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 To determine the co-receptor usage of p1579A-1 cloned virus, U87.CD4 cells expressing 
either the CXCR4 or CCR5 co-receptors were infected with virus containing supernatant 
equivalent to 30ng of HIV-1 p24 antigen. Virus growth was monitored by measuring p24 antigen 
in culture supernatant. p1579A-1 HIV-1 replicated more efficiently in U87.CD4 cells expressing 
CCR5 than CXCR4, indicating that p1579A virus is an R5 tropic virus (Table 3). Consistent with 
CCR5 co-receptor usage, p1579A-1 HIV-1 was found to be non-syncytia inducing (NSI), due to 
its inability to form syncytia in MT2 cells (data not shown).  
 
 
Table 3. Coreceptor usage of p1579A-1 cloned virus 
Coreceptor Usage-U87.CD4.CCR5/CXCR4  
  
  1579Aa Balb IIIBc
  CCR5 CXCR4d CCR5 CXCR4e CCR5f CXCR4 
D2 183 276 2,276 601 338 >200,000 
D4 705 210 99,275 650 425 >200,000 
D6 3,480 220 ND ND ND ND 
D8 12,770 280 ND ND ND ND 
D10 33,625 300 ND ND ND ND 
a,b,cHIV-1 p24 antigen production (pg/ml) in U87.CD4.CCR5 or U87.CD4.CXCR4 expressing cells.  
d,e,fAn increase in p24 value of at least 3-fold over the day 2 value is considered positive HIV replication.  
ND—not determined. 
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The complete sequence of the proviral DNA of p1579A-1 was determined by primer 
walking along the entire genome. The sequences were verified using the HIV-1 Sequence 
Locator tool at the Los Alamos HIV-1 sequence database and then manually joined. The full 
length genome of p1579A-1 is 9699 base pairs long. All reading frames of this clone were found 
to be open. The entire genome was subjected to HIV-1 recombination analysis at the Los Alamos 
Sequence Database and was not found to be an HIV-1 recombinant.  The complete genome of 
p1579A-1 and the long terminal repeat (LTR) were aligned with HIV-1 group M subtype 
reference sequences obtained from the Los Alamos HIV-1 database. Phylogenetic analysis of 
both the complete genome and the LTR showed that 1579A clusters within the HIV-1 subtype A 
lineage (Figures 12 and 13).  
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Figure 12. Phylogenetic analysis of p1579A-1.  
Neighbor-joining Jukes Cantor unrooted tree showing the phylogenetic relationship of the complete genomic 
sequence of p1579A-1 to HIV-1 group M reference subtypes. The scale bar at the bottom represents percent genetic 
divergence. 
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The envelope gene is important for viral attachment, infectivity and coreceptor usage. We 
analyzed the envelope gene by aligning the predicted amino acid sequence of p1579A-1 with 
those of the consensus sequence of reference subtypes A1 and A2 and IndieC1.  The 
characteristic GPGQ motif at the crown of the V3 loop was conserved in all sequences (Figure 
14) (43). Consistent with earlier findings of CCR5 coreceptor usage and an NSI phenotype, there 
was an absence of basic amino acids at positions 11 and 25 in 1579A (Figure 14). This was also 
true for IndieC1, as reported earlier (117). An analysis of potential N-linked glycosylation sites 
did not show any major differences between 1579A and reference subtype A1 or A2 obtained 
from the Los Alamos HIV database or Indie C1. The number of predicted potential sites ranged 
from 27-31; with IndieC1 having the most, 31 and 1579A having 29. Variations in the locations 
and number of sites were seen predominantly in the variable regions V1, V2, V4 and V5. Only 
one potential site was predicted for 1579A between positions 131-150 of the V1 region whereas 
at least 2 sites were predicted for other subtype A’s and 3 were predicted for IndieC1 (Figure 
14). Lack of potential N-linked glycosylation sites in this region is probably due to a 14 amino 
acid deletion in this region. Absence of glycans in this region could have an effect on CD4-
gp120 interaction and viral entry (118, 119). 
The long terminal repeat (LTR) is known to contain essential elements that control HIV-1 
transcription and hence replication. As a first step to explore biological differences between 
subtypes from India, we compared the LTR of p1579A-1 with the LTR of IndieC1 by 
performing a transcription factor binding site (TFBS) prediction analysis. Several differences 
were observed in the number of TFBS between subtypes A and C (Figure 15). Most notably, 
both p1579A-1 and IndieC1 were found to contain two NF-kappa B binding sites. This is in 
contrast to HIV-1 subtype C of African origin which has been shown to carry three functional 
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NF-kappa B enhancers. This is not unusual, since Indian subtype C has been shown to be 
genetically distinct from other HIV-1 subtype C around the world (13).  Furthermore, IndieC1 
and not p1579A-1 has the binding sites for GATA-binding factor 3 (GATA) and Octamer-
binding factor 1 (Oct1). Finally, p1579A-1 but not IndieC1 has the binding site for GC Box 
elements which have been reported to be a component of Vpr-mediated LTR activation (120). 
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Maximum likelihood unrooted tree showing the phylogenetic relationship of p1579A-1 long terminal repeat (LTR) 
sequence to the consensus (CONS) sequence of HIV-1 group M LTR. All HIV-1 group M reference sequences were 
obtained from the Los Alamos HIV Database (www.hiv.lanl.gov). The scale bar at the bottom represents percent 
genetic divergence. 
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Figure 13. Phylogentic analysis of LTR 
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Figure 14. Molecular characterization of HIV-1 p1579A-1 envelope gene.  
Amino acid alignment of p1579A-1, reference subtype A1 and A2 (subgroups of HIV-1 group M, subtype A) consensus sequences obtained from Los Alamos 
HIV-1 database and IndieC1 envelope gene. N=predicted N-linked glycosylation site. The GPGQ motif is surrounded by solid box. Positions 11 and 25 are 
represented by an asterisk (*). 
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EVI1
EVI1
SF1 PAX6 CMYB
CMYB
MEIS1
MEIS1
OCT1
VMAF
VMAF
MEIS1
NF-kappa B
NF-kappa B
NF-kappa B
NF-kappa B GCBOX AP4
AHRARNT
CREL
SMAD3
SP1
CP2 GATA NFAT
CP2
PAX6
U3 R U5
U3 R U5
p1579A-1 LTR
pIndie C1 LTR
AML3
Transcription Factor Binding Site Predictions 1579A Concensus A Indie C1
AHRARNT  (Aryl hydrocarbon receptor/Arnt heterodimers) 1 0 0
AML3           (Runt-related transcription factor 2/CBFA19core binding factor, runt domain, alpha subunit 1)) 1 1 0
AP4              (Activator protein 4) 1 1 0
CMYB          (c-Myb,important in hematopoesis,cellular equivalent to avian myoblastosis virus oncogene v-myb) 1 1 1
CP2              (LBP-1c(leader-binding protein-1c), LSF(late SV40 factor), CP2, SEF(SAA3 enhanced factor) 1 1 1
CREL           (c-Rel) 0 0 1
EVI1             (Ecotropic viral integration site 1 encoded factor) 1 1 1
GATA          (GATA-binding factor 3) 0 0 1
GC                (GC box elements) 1 1 0
MEIS1         (Binding site for monomeric Meis1 homeodomain protein) 2 2 1
NFAT          (Nuclear Factor of activated T-cells) 0 0 1
NFKAPPAB (NF-kappa B) 2 2 2
OCT1          (Octamer-binding factor 1) 0 1 1
PAX6          (PAX6 paired domain and homeodomain are required for binding to this site) 2 1 0
SMAD3       (Smad3 transcription factor involved in TGF-beta signaling) 0 0 1
SP1              (Stimulating protein 1 SP1, ubiquitous zinc finger transcription factor) 0 0 1
VMAF          (v-Maf) 1 0 1
 
(A) Chart listing predicted transcription factor binding sites. Values in each column represent the number of sites predicted for each transcription factor binding 
site. (B) Schematic representation of predicted TFBS within the LTRs of 1579A (upper) and IndieC1 (lower). 
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Figure 15. Analysis of HIV-1 long terminal repeat (LTR).  
3.6 DISCUSSION 
Out of 19 HIV-1 Indian isolates only one was found to be a subtype A. This finding is consistent 
with the low frequency (5-10%) of subtype A prevalence in India. From this HIV-1 subtype A 
isolate the molecular clone p1579A-1 was constructed. This clone was found to be replication 
competent in CD8-depleted PBMC and CCR5 tropic as determined by genotypic and phenotypic 
analysis. It is important to note that p1579A-1 was constructed based on unique restriction sites 
pre-existing within the genome and was not subject to changes in the sequence in order to 
generate these sites. Furthermore the complete cloned sequence was replication competent. It 
was unnecessary to provide genes in trans, reconstruct or substitute any parts in order to recover 
infectious virus which, depending on the location of the substitution, could alter the replication 
properties of the virus and not be representative of the parental isolate. Therefore p1579A-1 
represents biologically relevant virus isolated from an HIV-1 infected individual.  
Sequence analysis of p1579A indicated it to be of the HIV-1 subtype A lineage. The 
branching pattern also indicates that p1579A-1 is more closely related to the sub-subtype A2 
than A3. This may indicate an introduction of subtype A into India from the eastern region of 
Africa however more Indian subtype A analysis would be necessary to confirm this relationship. 
GATA 3 is a member of a family of transcriptional activating proteins and is expressed in 
T lymphocytes. In vitro studies have shown enhanced HIV-1 LTR-directed transcription in the 
presence of this protein (121). Octamer binding proteins (Oct) have been reported to both 
positively and negatively regulate the expression of a variety of genes (122, 123). In vitro studies 
have shown Oct-1 to either repress LTR-directed transcription of HIV-1 in fibroblasts (122) or to 
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have no effect on HIV-1 transcription in primary CD4 T cells (123). It can be hypothesized that 
the presence or absence of these binding sites in the LTR of subtypes C and A may be 
responsible for differences in replication efficiency, resulting in the higher prevalence of subtype 
C over other subtypes of HIV-1 in India. Further studies are necessary to evaluate this 
hypothesis.   
 In conclusion, p1579A-1 represents the first infectious molecular clone of HIV-1 subtype 
A which replicates in primary CD4 lymphocytes. Availability of a molecular clone of subtype A 
HIV-1 will be useful for the study of replication dynamics and evolution of subtypes in India. 
Furthermore, its full genomic sequence will be important for characterizing other HIV-1 subtype 
A around the world. 
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4.0  CHAPTER TWO.  GENETIC AND FUNCTIONAL CHARACTERIZATION OF 
THE LTR OF HIV-1 SUBTYPES A AND C CIRCULATING IN INDIA 
4.1 PREFACE 
This chapter is adapted from a manuscript accepted for publication in AIDS Research and 
Human Retroviruses. (Milka A. Rodrigueza , Chengli Shena, Deena Ratnera, Ramesh S. 
Paranjapeb, Smita S. Kulkarnib, Ramdas Chatterjeec , and Phalguni Guptaa. Genetic and 
Functional Characterization of the LTR of HIV-1 Subtypes A and C Circulating in India. 
Reprinted with permission from Mary Ann Leibert. Work described in this chapter is in partial 
fulfillment of specific aim 4.   
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4.2 ABSTRACT 
Genetic analysis of HIV-1 sequences circulating in different parts of India have shown that the 
predominant proportion of HIV-1 subtypes circulating in India is type C and a small fraction are 
subtypes A, B, E and CRFs. We sequenced the HIV-1 long terminal repeat (LTR) promoter 
region of seven subtype C and five subtype A isolates obtained from two major cities in India. 
Sequence analysis of the complete promoter and TAR regions revealed conserved subtype-
specific variability in several major binding sites. Three NF-κB sites were present in all subtype 
C isolates and two isolates contained an insertion in the most frequent naturally occurring length 
polymorphism (MFNLP). The transcriptional activity of one these isolates may have been 
hindered due to this insertion. Despite the apparent variability between the LTRs we did not 
observe any significant difference in the transcriptional activity between subtype C and subtype 
A. To our knowledge, this is the first study characterizing the genetic structure and functional 
attributes of subtype A LTRs from India. 
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4.3 INTRODUCTION 
In the current global epidemic, subtype C accounts for more than 50% of all infections and 
predominates in South and Eastern Africa, India and China (7). With a population of 1.1 billion, 
India has the second largest number of HIV infected individuals in the world next to South 
Africa. The estimated HIV prevalence among people 15-49 years old is 0.5%-1.5% (19). Greater 
than 90% of the infections in India are made up of subtype C (124). The asymmetric distribution 
of HIV-1 subtypes in India suggests that there may be a biological basis for such dissemination. 
Genetic diversity of the virus may likely play a key role. 
The long terminal repeat (LTR) of HIV regulates the expression of the viral genome 
through its interaction with both cellular and viral transcription factors (93). The HIV-1 LTR is 
approximately 640 base pairs long and is divided into 3 structural regions designated, U3, R and 
U5. The U3 region is further subdivided into the modulatory, enhancer and core/promoter 
functional regions (93, 94). The U3 region is of particular interest because it contains binding 
sites for several key transcription factors such as NF-κB, Sp-1, NF-AT, USF and TCF1-α, which 
regulate HIV transcription (94, 95). There is a growing body of data indicating subtype specific 
differences of the HIV-1 LTR at both the genetic and functional levels (95-99). The subtype C 
LTR in particular has been shown to contain three NF-κB binding sites instead of two that are 
carried by the majority of subtypes (101-103). The additional NF-κB enhancer site in subtype C 
has been correlated with increased promoter activity and increased viral replication (96, 98, 104, 
105). The purpose of this study is to characterize the genetic structure of the LTR of HIV-1 
subtype C and subtype A of Indian origin and to compare their functional domains. 
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4.4 MATERIALS AND METHODS 
4.4.1 Viruses, DNA isolation and HIV subtyping 
HIV-1 subtype C isolates and the subtype A isolate 1579A were  obtained from the peripheral 
blood mononuclear cells (PBMC) of HIV-1 positive Indian subjects from Calcutta, India by co-
culture with PHA-stimulated CD8-depleted normal donor PBMC as described previously (124). 
DNA isolation and HIV-1 subtyping was performed as described previously (124). HIV-1 
subtype A isolates A3, A6, A11 and A81 were obtained from Dr. Paranjape of the National 
AIDS Research Institute, Pune, India and subtyped by his laboratory. HIV-1 subtype C, IndieC1, 
was obtained from the molecular clone pIndieC1 (117). 
4.4.2 Construction of LTR-luciferase reporter plasmids 
The 5’ LTR region was amplified from chromosomal DNA of cultured cells using a nested PCR 
reaction. Outer PCR primers were IN-C LTR XhoI-F or IN-A XhoI-F (5’-
TACTCGAGTGGAAGGGTT AATTTACTCT-3’ or 5’-ATCTCGAGACTGGATGGG 
TTAATTTACT-3’, respectively) and SK101 (gag) (5’-GCTATGTCAGTTCCCCTTGGTTCTC-
3’). Nested PCR primers were IN-C LTR XhoI-F or IN-A XhoI-F (sequence above) and IN-C 
LTR Hind III-R or IN-A LTR Hind III-R (5’-ATA AGCTTACTGACTAAAAGGGTCTGAG-3’ 
or 5’-ATAAGCTTTGCTAGAGATTTTTACACCAACTAG-3’, respectively). Cycling 
conditions for both outer and nested PCR were the following: 1 cycle at 95°C for 2 min, 35 
cycles at 95°C for 15 sec, 55°C for 30 sec, and 68°C for 1 min, with a final extension at 68°C for 
3 min. All PCR reactions were performed with high fidelity AccuPrime Pfx DNA polymerase 
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(Invitrogen). The gel purified nested PCR product was cloned into pCR-Blunt II TOPO vectors 
(Invitrogen). Forward and reverse sequencing was performed using M13F/R primers. The LTR 
fragment was then subcloned into pBlue LTR-luciferase plasmid (NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID) using XhoI and HindIII restriction 
enzymes.  
4.4.3 Transcription factor binding site analysis and phylogenetic analysis 
Sequences were aligned and manually edited using Vector NTI suite (Informax, Oxford, UK). 
HIV-1 group M subtype reference sequences from the Los Alamos HIV database were used in 
the construction of phylogenetic trees. Phlyogenetic analysis was performed using MEGA. The 
distance matrix was generated by the Kimura two-parameter model whereas the tree topology 
was determined using the neighbor-joining method. Statistical significance of branchings and 
various clustering were assessed by bootstrap re-sampling of 1000 pseudoreplicates on the 
complete data set. 
4.4.4 Transfections 
Jurkat or Jurkat-tat T cells were transiently co-transfected with LTR luciferase reporter plasmids 
and the internal control plasmid pGL4.74 which expresses Renilla luciferase (Promega). 
Transfections were performed using Lipofectamine 2000 reagent (Invitrogen) and 0.5ug of 
reporter plasmid DNA and 0.05ug of control plasmid. Forty-eight hours post-transfection, the 
cells were lysed and assayed for luciferase activity using a dual luciferase reporter assay system 
(Promega).  
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GenBank Accession Numbers: 
 
EF592596, EF592597, EF592598, EF592599, EF592600, EF592601, EF592602, EF592603, 
EF592604, EF592605. 
 
4.5 RESULTS 
The LTR region from seven HIV-1 subtype C and five HIV-1 subtype A isolates from 
India were used in this study. A summary of patient characteristics is shown in Table 4. Figure 
16 shows an unrooted phylogenetic tree of Indian subtype C and subtype A LTRs and HIV-1 
group M LTR sequences. All of the Indian subtype C LTR clustered with subtype C. Five out of 
seven clustered within Indian subtype C. Two out of seven, C34 and C298, branched outside of 
the Indian subtype C lineage. These LTRs may be representative of separate introductions of 
subtype C into India. All of the Indian subtype A LTRs clustered within subtype A and formed 
their own sub-cluster with a moderate bootstrap value of 70. The 1579A isolate, although 
obtained from the eastern region of India, appears to be related to the subtype A isolates obtained 
from the southwestern region of the country.  
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Table 4. Characteristics of HIV-1 infected subjects from India 
A
A
A
A
A
C
C
C
C
C
C
C
Subtype 
R5
R5
R5
R5
R5
R5
R5
R5
R5
R5
R5
R5
Coreceptor
Usage
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
Phenotype
N/AasymptomaticPuneM45A81
477soar  throat, weight loss CalcuttaF16A15
905asymptomaticPuneF23A11
N/AasymptomaticPuneM30A6
N/AasymptomaticPuneM23A3
233N/ACalcuttaF24C298
298
enlarged lymph nodes, skin 
rashes CalcuttaF24C293
255abdomen pain, leuchorrhoeaCalcuttaF25C267
736weakness, anorexiaCalcuttaF16C59
N/AN/ACalcuttaN/AN/AC34
343abdomen pain, diarrheaCalcuttaF25C31
N/ANDNDNDNDpIndieC1
CD4 
Count Clinical SymptomsCity of IsolationSexAgeIsolate ID#
 
ND or N/A = information not available 
NAD = nothing abnormal detected 
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 C.IN.93.93IN101 AB023804
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 C267
 C.IN.93.93IN9999 AF067154
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 C.IN.94.94IN11246 AF067159
 C59
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 C.BW.96.96BW01B03 AF110959
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 K.CD.97.EQTB11C AJ249235
 F1.BE.93.VI850 AF077336
 H.BE.93.VI991 AF190127
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 B.FR.83.HXB2 LAI IIIB BRU K03455
 B.US.83.SF2 K02007
 B.TH.95.95TH85 AF196708
 B.US.83.RF M17451
 D.KE.93.MB2059 AF133821
 D.MZ.97.97MZ36 AF196726
 G.BE.96.DRCBL AF084936
 U.CD.96.96ZR29 AF196737
 A.RW.92.92RW60 AF196741
 A1.SE.94.SE7253 AF069670
 A.TZ.93.93TN68 AF196743
 A1.UG.92.UG029 AB098332
 A1.KE.94.Q23 17 AF004885
 A3
 A81
 A11
 A6
 A15
85
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97
70
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93
98
94
73
0.02  
Figure 16. Phlylogenetic analysis of LTR sequences.  
Neighbor-joining Kimura two-parameter unrooted tree showing the phylogenetic relationship of HIV-1 subtype A 
and subtype C LTRs to other HIV-1 group M LTRs. Triangle = subtype C LTR patient isolates. Circle = subtype A 
LTR patient isolates. The scale bar at the bottom represents percent genetic diversity.  
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 The LTRs were analyzed for potential transcription factor binding sites (TFBS) using 
TESS. Several subtype specific variations were observed between subtype A and C LTRs 
(Figure 17). The NF-κB enhancer motifs were highly conserved and were in agreement with 
previously published reports that subtype C contained an additional NF-κB motif. GATA-3 is a 
member of a family of transcriptional activating proteins expressed in T lymphocytes. The 
GATA-3 site was highly conserved among both subtypes. In the subtype A LTR 4 out of 5 
contained an A and 1 contained a T at position -449 of the GATA-3 binding site while in the 
subtype C LTR, 4 out of 7 contained a G, 2 contained a C and 1 contained an A at that same 
position. The significance of these changes and effects on transcriptional activity are unclear. 
The NF-AT sites I and II were the most variable among all of the predicted TFBS and contained 
several subtype-specific sequence variations. The upstream regulatory factor (USF), along with 
NF-AT, is one of several positive regulatory regions contained within the negative regulatory 
element (NRE) of the HIV-1 LTR (94, 101). We found several subtype specific changes within 
the USF and subtype specific signature sequences within the core NRE (positions -174 to -163 of 
HXB2). The core NRE sequence within the USF for subtype C (CRCAGACACNB) was only 
moderately conserved. However, the core NRE was highly conserved among subtype A 
(CTAAAACACAG) - with 2 isolates each having 1 base change compared to the consensus 
sequence of subtype A isolates analyzed in this study. T cell specific factor (TCF-1 alpha) was 
highly conserved with subtype specific variations. The most frequent naturally occurring length 
polymorphism (MFNLP) within the LTR region is located upstream of the NF-κB site at position 
-120 of HXB2 and can be from 15 to 34 bp long (94, 125). We observed two subtype C LTRs 
which contained insertions in this region. Isolate C31 contained a 6bp insertion while isolate C59 
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contained a 20bp insertion. Interestingly, we observed that the LTR from isolate C59 also had 
the lowest luciferase activity among all of the LTRs (Figure 18). This reduced activity may be 
due the binding of a nuclear factor which is identical to RBF-2 which has a negative effect on 
transcriptional activity (125). Sp1 sites, which are important for LTR activation, have been 
reported to be highly conserved across subtypes (95). Analysis of Indian subtype A and C LTRs 
showed that the Sp1 sites were also highly conserved with subtype-specific sequences. The 
TATA box was strictly conserved among all subtypes.  
The TAR motif located within the R region of the HIV-1 LTR is an RNA transcriptional 
control recognition sequence that forms a hairpin stem-loop structure to which the viral Tat 
protein binds. Binding of Tat to the trinucleotide bulge of the TAR hairpin triggers a series of 
events that allows increased processivity of transcriptional complexes resulting in the efficient 
production of full-length transcripts and a marked increase of viral gene expression (88). We 
found that LTRs from all subtype A and one subtype C (C59) contained the C24T change (94).  
We also observed that there was a deletion at position 25 within the TAR bulge region of all 5 of 
the subtype A LTRs.  
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Figure 17. Alignment of subtype C and subtype A LTR’s.  
Transcription factor binding sites (TFBS) and regulatory regions are shaded. Identical sequence indicated by dots; insertions/deletions indicated by dashes. 
To evaluate and compare the transcriptional activity of subtypes A and C of Indian origin 
a luciferase reporter assay was used. We observed no significant difference in the LTR 
transcriptional activity between subtypes C and A either in the absence (p=0.10) or presence 
(p=0.59) of HIV-1 Tat protein (Figure 18). As mentioned earlier, isolate C59 had the lowest 
transcriptional activity among all of the isolates tested. We speculate that this may be due to the 
20bp insertion within the MFNLP. We also compared the transcriptional activity of the LTR of 
subtype C and subtype A after stimulation with increasing dosages of TNF-alpha (10ng-810ng) 
or PMA (10ng-30ng) and observed no significant difference (p=0.10) between the two groups 
(Figure 19). 
.
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Figure 18. Comparison of transcriptional activity between subtype C and subtype A of Indian origin.  
 
Transcriptional activity was evaluated in either the absence (A) or presence (B) of HIV-1 tat protein. A two sample 
t-test between the average relative value of light units of HIV-1 subtype A and subtype C LTRs was performed..(A) 
p=0.10, (B) p=0.59. Relative transcription refers to the average light units of each subtype-specific LTR relative to 
isolate C31.  
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Figure 19. Transcriptional activity of HIV-1 subtype A and subtype C LTR after stimulation.  
 
Transfected cells were cultured with increasing concentrations of TNF-α or PMA for 24 hours. Luciferase activity 
was measured 48 hours post-transfection. IFN-κB luciferase reporter plasmid was used as a positive control.  
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4.6 DISCUSSION  
This study has described the HIV-1 LTR subtype-specific variability among viruses circulating 
in India. We did not observe any significant differences in the transcriptional activity between 
subtypes C and A, however we used a subtype B HIV-1 Tat protein for the transcriptional 
analysis and therefore speculate that the corresponding subtype specific LTR/Tat combination 
could potentially yield different results. Further transcriptional analysis should be performed 
with Tat protein from subtype C and subtype A from India.  We have observed a significant 
difference in the in vitro replication fitness of subtypes C and A from India (unpublished data). 
In these studies subtype C primary isolates almost always outcompeted subtype A primary 
isolates and overall, subtype C had higher in vitro replication fitness in dual infection growth 
competition assays than subtype A. The study described here suggests that such replication 
fitness differences between subtype C and subtype A may not be due to differences in LTR 
function among these two subtypes. Furthermore, isolate C59 which displayed the lowest LTR 
transcriptional activity, had among the highest replication fitness values in dual infection growth 
competition assays. In fact a recent study which investigated HIV-1 subtype C LTRs from 4 
different regions of India observed similar insertions and identified them as de facto AP-1 
binding sites (102). They showed that oligonucleotides spanning the putative AP-1 site 
efficiently bound recombinant c-Jun (AP-1) protein although with lower affinity than wild type 
AP-1. AP-1 has been reported to have a positive effect on transcriptional activity (95, 126). 
Therefore functional studies of these subtype C LTRs are necessary to determine the effect of 
this insertion on transcription. These results suggest that there is a more complex interplay of 
virus and host cell factors which determines replication capacity and possibly the eventual spread 
  78
of a particular variant within a population. More extensive studies are necessary to determine the 
nature of these factors and how best to manipulate them to control the current HIV-1 epidemic. 
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5.0  CHAPTER THREE. HIGHER REPLICATION FITNESS AND TRANSMISSION 
EFFICIENCY OF HIV-1 SUBTYPE C THAN HIV-1 SUBTYPE A FROM INDIA: 
IMPLICATIONS FOR SUBTYPE C PREDOMINANCE 
5.1 PREFACE 
This chapter is adapted from a manuscript in preparation (Milka A. Rodrigueza, Ming Dinga, 
Deena Ratnera, Yue Chena, Ramesh S. Paranjapeb, Smita S. Kulkarnib, Ramdas Chatterjeec, 
Patrick M. Tarwaterd and Phalguni Guptaa). Work described in this chapter is in fulfillment of 
specific aims 2, 3 and 4. 
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5.2 ABSTRACT 
HIV-1 subtype C has been the predominant subtype throughout the course of the HIV-1 
epidemic in India regardless of the geographic region of the country. In this study we have 
investigated the in vitro replication fitness of HIV-1 subtypes A and C from India in an effort to 
understand the mechanism of subtype C predominance in this country. Using a dual infection 
growth competition assay, we found that primary HIV-1 subtype C isolates had higher overall 
relative fitness in PBMC than subtype A primary isolates. Moreover using an ex vivo cervical 
tissue derived organ culture, subtype C isolates displayed higher transmission efficiency across 
cervical mucosa than subtype A isolates. To determine whether the envelope gene is responsible 
for increased replication fitness in PBMC and higher transmission efficiency of subtype C, we 
constructed a half-genome recombinant clone of subtype A in which the 3’ half of the viral 
genome was replaced with the corresponding subtype C 3’ half. This A/C recombinant virus had 
lower replicative fitness and transmission efficiency than the parental subtype A, but exhibited 
higher replicative fitness than the parental subtype C. These results suggest that the higher 
replication fitness and transmission efficiency of subtype C virus compared to subtype A virus 
from India is not due to envelope gene alone and may be due to a complex interaction between 
the genes located within the two halves of the viral genome. These data provide a model to 
explain the asymmetric distribution of subtype C over other subtypes in India. 
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5.3 INTRODUCTION 
Human immunodeficiency virus (HIV) – 1 was introduced into the human population 
through 3 separate cross-species transmissions from non-human primates in Africa (1, 4). Each 
of these transmission events is represented by phylogenetic groups termed Group M, Group O 
and Group N. HIV-1 Group M, which is responsible for the global pandemic, is further 
subdivided into 9 genetic groups (A – D, F – H, J and K) called subtypes or clades, based on 
sequence diversity in the env gene.  Subtype C has now become the most predominant HIV-1 
variant and accounts for more than 50% of infections worldwide. It is mainly concentrated in 
South and Eastern Africa, India and China.  
In India, HIV-1 has spread rapidly throughout the country where it has been reported in 
nearly every major city.  Heterosexual transmission is the major route of transmission. There are 
an estimated 5 million people living with HIV-1 in India, 90-95% of which are subtype C 
infections. Genetic analysis of HIV-1 circulating in India indicates that the current epidemic is 
the result of one or very few introductions of HIV-1 into the country. Therefore the 
preponderance of subtype C viruses cannot be explained by new and continual introductions of 
HIV-1 subtype C into the country. While there may be several factors contributing to subtype C 
predominance, this asymmetric distribution of HIV-1 subtype C over other subtypes in India 
suggests that there may be a biological basis for such dissemination. Some explanations for the 
asymmetric distribution of HIV-1 subtypes in India include: founder effects, human genetic 
susceptibility and viral attributes such as transmission efficiency and replication fitness of 
different subtypes of HIV-1. 
Fitness is an evolutionary term used to describe the ability of an organism to reproduce 
and adapt to its particular environment (39). For RNA viruses, fitness can be estimated by the 
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relative ability to produce stable infectious progeny in a given environment (39). HIV fitness can 
be affected by any combination of factors encountered during viral replication or host factors 
such as immune or drug pressure (106, 127). Several studies have investigated HIV fitness as it 
relates to drug resistance, disease progression and pathogenesis and also the fitness of HIV 
genetic variants as they relate to transmission efficiency and the global distribution of subtypes.  
The seminal study examining this issue comes from the work of Quinones-Mateu et al. 
(51). Using a dual infection growth competition assay (GCA), they examined relative fitness of 
virus isolates obtained from slow and rapid progressors as well as those representing R5 and X4 
phenotypes. They found that virus isolates from long term nonprogressors were out-competed by 
viruses from rapid progressors. Similarly, X4/syncytium inducing (SI) viruses generally out-
competed R5/non-syncytium inducing (NSI) viruses, although some exceptions were noted. This 
study also showed that there is a correlation between ex vivo fitness and disease progression. 
HIV-1 isolates from progressive patients were shown to be significantly more fit than HIV-1 
isolates from long-term survivors – in several cases independent of viral phenotype. This study 
was useful in demonstrating that fitness values may serve as a predictor of progression to AIDS. 
With a few HIV-1 isolates they have shown a difference in replication fitness among several 
non-C subtypes of HIV-1. However, given the limited number of experiments and strains used in 
competitive studies between different subtypes, it is not clear if a particular subtype of viruses 
has a clear advantage with respect to replication fitness. 
In a later study, Ball et al. (52), compared the ex vivo fitness of CCR5-tropic HIV-1 
isolates of subtypes B from Brazil and US and subtype C mostly from Africa in PBMC, CD4+ T 
cells, macrophages and Langerhans cells using a dual infection growth competition assay. All 
subtype C isolates were outcompeted by subtype B isolates in all cell types, except in 
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Langerhans cells. In the Langerhans cells, subtype C demonstrated competitive replication 
efficiency against subtype B. This observation is important when one considers the fact that 
Langerhans cells in the cervix have been implicated for HIV-1 transmission across the cervical 
mucosa. This study was useful in generalizing the relative fitness of HIV-1 subtype C virus, but 
is not sufficient to characterize the fitness of Indian type C viruses, due to the recent findings that 
they are different than most of the other subtype Cs in the world. We and others have shown that 
Indian subtype C sequences (CIN, C3) are distinct from subtype C sequences from 23 other 
countries (13, 35, 36). Specific amino acid substitutions within env were found to be 
distinguishing characteristics within this Indian type C lineage (13, 36).  
 In this study we have therefore compared between HIV-1 subtypes A and C from India 
the in vitro replication fitness in PBMC using a GCA and transmission efficiency across cervical 
mucosa using a cervical tissue derived organ culture.  HIV-1 subtype A primary isolates were 
outcompeted by HIV-1 subtype C primary isolates in PBMC obtained from six US and two 
Indian donors. Furthermore, most of the subtype C had higher transmission efficiencies than 
subtype A when cervical tissues were challenged with a mixture of subtype A and subtype C 
viruses.  
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5.4 MATERIALS AND METHODS 
5.4.1 Viruses.  
Seven primary isolates (C31, C59, C267, C293, C298 and 1579A) were isolated from PBMC of 
HIV-1-infected subjects at Chittaranjan Cancer Research Institute in Calcutta, India. Virus 
isolation was performed as described previously (111, 112). Briefly, PBMC from HIV-infected 
Indian patients were cultured in the presence of phytohemagglutin (PHA)-stimulated, CD8-
depleted normal donor PBMC in RPMI 1640 media supplemented with IL-2. Virus 
growth/expansion was monitored by HIV-1 p24 production in the culture supernatant and 
harvested every 5 days for 40 days. Harvested virus was expanded in phytohemagglutin (PHA)-
stimulated, CD8-depleted normal donor PBMC in RPMI 1640 media supplemented with IL-2 as 
described previously (124). Four other primary subtype A isolates (A3, A6, A11 and A81) were 
obtained from the National AIDS Research Institute in Pune, India. In addition, the HIV-1 
infectious molecular clone IndieC1 was obtained from the molecular clone pIndieC1 kindly 
provided by Dr. M. Tatsumi (117).  Coreceptor usage and MT2 assay for syncytia formation 
were conducted as described previously (124). The infectivity titer for each isolate was 
determined by measuring HIV p24 production after 7 days using an endpoint dilution assay. The 
tissue culture dose for 50% infectivity (TCID50) was calculated using the Spearman-Karber 
formula.  
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5.4.2 Growth Competition Assays.  
PBMC were purified from 5 US blood bank donors (racial and ethnic backgrounds unknown) 
and 2 Indian donors (IRB approved) by Ficoll-Hypaque density centrifugation. CD8-depleted 
PBMC isolated from PBMC using immunomagnetic beads, were stimulated overnight with PHA 
and treated with 5ug/ml polybrene for 1 hour prior to infection. For each GCA, 3 x 105 PHA-
stimulated cells were infected either singly or dually with subtype A and C viruses at TCID50 
ratios of 1:1 or 1:0.1 at 37°C overnight in a 48-well plate. The next day the cells were pelleted 
and the virus supernatant was removed. The cell pellet was then resuspended in 750ul IL-2 
media and divided equally to three wells (100,000 cells/well) in a 96-well plate (Figure 20). All 
competition experiments were performed in duplicate. One hundred microliters of cell free 
supernatant was collected at 7, 14 and 21 days and analyzed for the level of subtype specific 
RNA by real-time RTPCR. Virus growth was monitored every 7 days by measuring HIV-1 p24 
antigen in the culture supernatant. 
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Figure 20. Schematic representation of dual infection growth competition assay procedure (A) and 
plate set-up (B).   
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5.4.3 Organ Culture.  
Ectocervical tissues were obtained from HIV seronegative premenopausal women with no 
history of STDs or cancer, undergoing hysterectomy or anterior/posterior repair procedures. The 
organ culture was set up as previously described (88). Briefly, a 6mm biopsied cervical tissue 
was placed into the Transwell™ with the epithelial layer oriented upwards and sealed around its 
perimeter with 3% agarose. The tissue containing Transwell™ was then placed into a 12-well 
plate containing 1ml of RPMI-1640 media supplemented with 10% FBS. A Transwell with the 
membrane only served as a positive control while a Transwell with agarose only served as a 
negative control. To study the transmission of virus, 150ul of cell-free HIV-1 subtype A and C 
virus either alone or mixed at a ratio of 1:1, was added to the tissue containing well and the 
positive and negative control wells, and incubated at 37°C for 3 days. Each transmission pair was 
tested in at least triplicate. On the third day, the tissue was removed and the culture supernatant 
in the bottom chamber was centrifuged at high speed (22,00rpm) to pellet the transmitted virus. 
The level of subtype specific HIV-1 RNA in the pellet was quantitated using TaqMan® real-time 
RTPCR. To ensure that transmitted virus was not due to leaks in the system, at the end of each 
experiment the intactness of the tissue was evaluated by examining transmission of blue dextran 
through the tissue and agarose control wells.  
5.4.4 RT-PCR and TaqMan real-time PCR.  
To quantify the relative proportion of HIV-1 subtype A and C in culture fluid of GCA or 
transmission studies, subtype specific primers for the gag-p17 region of the genome were used in 
a TaqMan® real-time PCR assay. Standard curves from 106 to 1 copy were generated using 
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p1579A-1 or pIndieC1 molecular clones (117). The concentrations of the clones were 
determined by spectrometry at 260nm. Primers and probes for real-time PCR analysis were 
designed using Primer Express® software version 2.0. The subtype A specific primers used were 
gagAF153-178 (5’-CTGGTGAGTACGCCAATTTTTG-3’) and gagAR276-258 (5’-
CCCCTGGCCTTAACCGAAT-3’). The subtype C specific primers used were gagCF150-174 
(5’-CGACTGGTGAGTACGCCAATTTTA-3’) and gagCR270-243 (5’-
GCCTTAACCTAATTTTTTCCCATTTATC-3’). The probe used was universal and recognized 
by both subtype A and C variants; gagP-florochrome 205-187 (5’-
ATCTCTCTCCTTCTAGCCT-3’). 100-1000µl culture supernatant equivalent RNA was applied 
for reverse transcription using TaqMan® reverse transcription reagents (AppliedBiosystems) 
according to the manufacture’s protocol. A 30µl TaqMan® PCR was performed by mixing 5µl 
cDNA with TaqMan® Universal PCR Master Mix (AppliedBiosystems), 333nM each of forward 
and reverse primer and 250nM FAM/ MGB labeled probe. ABI Prism 7000 Sequence Detection 
System was used to carry out Real-Time PCR using the following cycling condition: 50 ºC for 2 
min, 95 ºC for 10 min, 45 cycles of 95 ºC for 15 sec and 60 ºC for 1 min. Serial diluted plasmid 
DNA ranging from 1 to 106 were applied to each PCR assay for a standard curve. No Template 
Control was included in each assay as well to guard against cross contamination.  Each sample 
was run in triplicate. ABS Prism 7000 SDS Software (Applied Biosystems) was used for PCR 
data analysis and HIV copy number estimation. To quantify the relative proportion of half-
genome A/C recombinant virus and parental subtype C virus using TaqMan®  real-time PCR, 
gag subtype-specific primers and gag universal probe was used for infections with pIndieC1 
parental virus and the A/C recombinant half-genome virus. To quantify parental p1579A virus 
and half-genome A/C recombinant virus, envelope gene subtype specific primers and probes 
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were used. The env subtype A specific primers used were 1579A-F (5’-
TCTGTGTCACTTTAAATTGTAGCAATGT-3’) and 1579A-R (5’-
TCTGTGGTCATATTGAAAGTGCAGTT-3’). The env subtype A specific probe used was 
1579A-P (5’-TTTACTTCCTGTGTGTTATT-3’). The subtype C specific primers used were 
IndC1-F (5’-CAAAGCCTAAAGCCATGTGTAAAA-3’) and IndC1-R (5’-
GCTCCCATTGTAGGTATTATAACTGCTA-3’). The subtype C specific probe used was 
IndC1-P (5’-TCTGTGTCACTTTAGAATGTAGA-3’). Standard curves, reaction conditions and 
cycling conditions were as described above for gag.  
5.4.5 Construction of A/C half-genome recombinant virus.  
Construction of a half genome A/C recombinant clone involved use of the available unique 
restrictions sites in the infectious molecular clone of subtype A HIV-1 1579A. The 3’-half (tat-
3’LTR) of pIndieC1 was PCR amplified with a forward primer containing a BamHI site and a 
reverse primer containing a BstEII site. The PCR product was subsequently subcloned into the 
pCR Blunt II TOPO vector (Invitrogen). All PCR reactions were carried out using the high 
fidelity AccuPrime Pfx DNA polymerase (Invitrogen). p1579A and the 3’-half of pIndieC1 were 
digested with BamHI and BstEII and the corresponding genomic halves were ligated together. 
The resulting clones obtained from the ligated mixture were used in the transfection of HEK293 
T cells followed by expansion of the virus containing  supernatant in CD8-depleted PBMC.  
  90
5.4.6 Estimation of viral fitness.  
Viral fitness was calculated by measuring relative viral RNA concentration of subtype A and C 
in culture supernatant as described by Quinones-Mateu et al. (51).  Briefly, the final ratio of 
virus produced in dual infections (f0) was divided by the initial ratio of virus in the inoculum (i0) 
to derive a single relative fitness (w) value (w=f0/i0). An average relative fitness value (wn) was 
estimated for each variant in dual competitions, where wn = the average fitness value for each 
timepoint based on all TCID 50 ratios. The ratio of relative fitness values of each HIV-1 variant 
in the competition is a measure of the fitness difference (WD) between both HIV-1 strains 
(WD=WM/WL), where WM and WL correspond to the relative fitness of the more and less fit 
viruses, respectively. A WD > 1 corresponds to the more fit variant. A WD < corresponds to the 
less fit variant. A WD = 1 corresponds to equal fitness of the two variants (41, 51) 
5.4.7 Trans suppression assay. 
Culture supernatant from subtype C or A infected CD8-depleted PBMC at day 15 was filtered 
followed by depletion of virus by high speed centrifugation at 22,000rpm for 1 hour at 4°C. One-
hundred thousand CD8-depleted PBMC were then pre-treated with the virus-free supernatant or 
cell culture supernatant from uninfected cells or media for 4 hours at 37°C. After pre-treatment, 
the cells were spun down and the supernatant removed. Pre-treated cells were infected with 
200ul of 3.8x106 TCID 50/ml HIV-1 subtype A (~30ng p24 protein) overnight in a 24-well plate. 
The next day the virus was removed and the cells were resuspended in a final volume of 10%, 
20% or 50% virus-free supernatant from subtype A or C infected cells. The final culture volume 
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was brought up to 250ul with RPMI-1640 media supplemented with IL-2. Virus growth was 
estimated by HIV-1 p24 in the culture supernatant at day 7 post infection.  
  
5.4.8 Statistical analysis. 
Average RNA copy numbers were calculated from each duplicate virus in the competition. Two 
sample t-test of the copy number means and Mann-Whitney (nonparametric) were used for 
comparison of subtype A group and subtype C group at day 7 and day 14, for assessment of 
statistical significance.  
WD values were calculated as described above. One sample t-test was used to determine 
whether the log relative WD was significantly different from WD = 0. For all analyses, the level 
of significance was set at p = 0.05.   
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5.5 
 
RESULTS 
5.5.1 Characterization of HIV-1 isolates and subtype determination.  
All of the viruses used for this study were obtained from HIV-1 infected individuals from India. 
HIV-1 isolates A3 - A81 are primary subtype A isolates obtained from Pune, a city in the 
southwest region of India. Primary HIV-1 subtype C isolates C31 - C298 and subtype A isolate 
A15 were obtained from Calcutta, a major city in the eastern region of India. A summary of 
patient information and viral characteristics is shown in Table 5. HIV-1 subtypes were assigned 
to each of the isolates based on DNA sequences within the env and gag genes and the LTR. To 
determine the coreceptor usage, U87.CD4 cells expressing either the CXCR4 or CCR5 
coreceptors were infected with virus supernatant and virus growth was monitored by measuring 
p24 antigen in the culture supernatant. All of the primary isolates used in this study replicated 
more efficiently in U87.CD4 cells expressing CCR5 than CXCR4, indicating that they are all R5 
tropic viruses. Consistent with CCR5 coreceptor usage, all isolates were found to be non-
syncytia inducing (NSI) due to their inability to form syncytia in MT2 cells.  
AA
A
A
A
C
C
C
C
C
C
C
Subtype 
R5
R5
R5
R5
R5
R5
R5
R5
R5
R5
R5
R5
Coreceptor
Usage
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
NSI
Phenotype
N/AasymptomaticPuneM45A81
477sore throat, weight loss CalcuttaF16A15
905asymptomaticPuneF23A11
N/AasymptomaticPuneM30A6
N/AasymptomaticPuneM23A3
233N/ACalcuttaF24C298
298
enlarged lymph nodes, skin 
rashes CalcuttaF24C293
255abdomen pain, leucorrhoeaCalcuttaF25C267
736weakness, anorexiaCalcuttaF16C59
N/AN/ACalcuttaN/AN/AC34
343abdomen pain, diarrheaCalcuttaF25C31
N/ANDNDNDNDpIndieC1
CD4 
Count Clinical SymptomsCity of IsolationSexAge
Isolate 
ID#
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Table 5. Indian patient information and virus characteristics 
ND or N/A – not determined, information unavailable 
R5 – CCR5 coreceptor 
NSI –Non-syncytia inducing 
 
 
5.5.2 Standardization of HIV-1 RNA quantitation.  
To quantify the viral RNA concentration in dually infected cultures we have standardized a 
subtype-specific real-time RTPCR that can quantify subtype A and subtype C in a mixture of 
these two subtypes. Using a number of TaqMan® cycling conditions, proviral DNA from 
subtype A and C infected PBMC and several primer-probe pairs we were able to obtain gag 
specific primer pairs and cycling conditions which could distinguish between and specifically 
amplify both subtypes. Figure 21A shows that using TaqMan® PCR cycling conditions, subtype 
C primers only amplified the HIV-1 subtype C proviral DNA. Likewise, subtype A primers only 
amplified HIV-1 subtype A proviral DNA. Based on these results we constructed standard curves 
to quantitate the relative proportion of viral variants in dual infections using full length molecular 
clones of HIV-1 subtype A and C. Each plasmid clone was serially diluted from 106 to 1 copy 
per reaction and analyzed in triplicate. Figure 21B shows that the assay had a linear range of 
detection from 101  to 106  copies/ml of subtype C and subtype A and the amplification  efficiency 
for each subtype specific primer set was nearly identical. Furthermore, we observed that even in 
the presence of non-specific template, both primer sets were able to maintain subtype specificity 
and the same amplification efficiencies (Figure 21B).  
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Figure 21. Optimization of primers and probes for TaqMan® real-time PCR for detection of 
subtypes A and C in a GCA.  
 
A) Gel image of PCR products generated using subtype A or subtype C proviral DNA and subtype specific primers. 
C-F/R and A-F/R indicate subtype C or subtype A specific primers used in the PCR reaction (respectively). Lanes 1 
– 11 each lane represents proviral DNA from PBMC infected with a different HIV-1 subtype C virus. Lanes 12 – 16 
each lane represents proviral DNA from PBMC infected with a different HIV-1 subtype A virus. B) Standard curves 
of subtype A and subtype C. Oval indicates a real-time PCR assay in which primers and probes were tested by 
combining 5x105 copies of HIV-1 subtype A and C plasmid DNA. Ct value = Cycle threshold value.  
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5.5.3 Estimation of viral fitness in PBMC by GCA.  
It has been well established that the best way of detecting differences in replicative 
fitness is by dual infection growth competition assays (GCA). This is due to the fact that these 
assays provide an internal control for the growth environment and is better able to detect smaller 
differences in fitness than monoinfections (49). Several methods have been employed to estimate 
the fitness of viral variants in GCA. It has been recently shown that TaqMan real-time PCR is a 
suitable method of detection and quantification of two competing HIV-1 variants in a GCA and 
is less labor intensive and more sensitive than previously used techniques such as HTA (128). 
Therefore, in our study we have applied the TaqMan real-time PCR technique to estimate the 
viral fitness of subtype A and C from India in a GCA.  
For our GCA experiments, we performed nineteen dual infections using seven subtype C 
(six  primary and one molecular clone) and five subtype A  isolates  (four primary and one 
molecular clone). These competitions were performed in various combinations in six different 
blood donors. In these assays CD8-depleted PBMC from US blood bank donors were either 
dually or singly infected with each virus subtype at varying TCID50 ratios. The proportion of 
each variant in the culture supernatant was measured every 7 days by TaqMan© real-time PCR. 
Figure 22 shows a representative GCA, showing HIV-1 RNA concentration in monoinfections 
and in dual infections of subtype A and C at both 1:1 and 1:0.1 TCID 50 ratios, respectively at 
days 7 and 14 after infection.  At both of these two days tested, there was no significant 
difference in the relative copy numbers in monoinfections, while in dual infections subtype C 
clearly outcompeted subtype A by day 7 at both 1:1 and 1:0.1 (A:C) TCID 50 ratios. We 
observed similar results in all other competitions between subtype A and C, however in some 
cases at TCID 50 ratios of 1:0.1 (A:C) subtype A was not outcompeted by subtype C until day 
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14. Figure 23 shows a summary of all GCAs performed with subtype A and C at days 7 and 14 at 
a 1:1 TCID 50 ratio. The data indicate that there was a significant difference in the RNA copy 
number of subtype C isolates compared to subtype A isolates (at D7 p <0.001, at D14 p<0.001). 
Table 6 shows the estimated relative fitness values (w) and fitness difference (WD) for each pair 
of isolates used in the GCA at day 7. With the exception of pIndieC1 in competition with the 
primary isolate A3, all subtype C viruses had a fitness difference value that was at least 3-fold 
higher than subtype A viruses. At day 7 the mean WD for all subtype C viruses tested was 58.3 
with a range of 1.0 – 255.5, while the mean WD for all subtype A viruses tested was 0.2 with a 
range of 0.0 – 0.3. Similar results were obtained at day 14. The mean WD for subtype C viruses at 
day 14 was 57.8 with a range of 0.4 – 226.4, while the mean WD for subtype A viruses at day 14 
was 0.4 with a range of 0.0-2.7 for day 14. Overall the mean WD for subtype C viruses at all 
timepoints for both TCID50 ratios was 58.4 with a range of 0.6 – 261.3, while the overall mean 
WD for subtype A viruses was 0.2 with a range of 0.0 – 1.5. 
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Figure 22. Representative GCA showing relative copy numbers of subtype A and C isolates in 
monoinfections and dual infections determined by TaqMan real-time PCR.  
 
Pink squares = subtype C, Blue diamond = subtype A. Single pink square at day 7 of 0.1:1TCID50 ratio indicates 
equal number of copies for subtype A and C.   
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Relative HIV-1 RNA copy numbers are expressed as log base 10 values.  Line indicates log base 10 value of the mean of the RNA copy numbers.  
Figure 23. Summary of relative copy numbers of all GCA’s performed at days 7 and 14 and 1:1 and 1:0.1 (A:C) TCID50 ratios.  
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 Table 6. Relative fitness and relative fitness fold difference values of day 7 GCA using PBMC from 
US donors 
7.10.13.0 ± 0.290.4 ± 0.07pInC1:A81
1.01.01.0 ± 0.191.0 ± 0.14pInC1:A3
21.80.04.40.2C298:A15
7.90.12.90.4C267C:A15
110.40.05.6 ± 0.120.1 ± 0.02C267:A3
255.50.05.7 ± 0.080.0 ± 0.01C59:A15
28.50.04.9 ± 1.070.2 ± 0.17C59:A11
10.90.13.5 ± 0.090.3 ± 0.01C59:A6
175.50.05.6 ± 0.140.1 ± 0.03C31:A15
19.90.14.6 ± 0.030.2 ± 0.01C31:A11
3.30.32.2 ± 0.830.7 ± 0.12C31:A6
Relative WD(C/A) ‡Relative WD(A/C) ‡Relative WC †Relative WA †GCA Pairs
 
† Relative fitness w = f0/i0, where: f0 = final ratio of virus produced in dual infections and  i0 = initial ratio 
of virus isolate in the inoculum. Relative fitness values are based on 1:1 and 1:0.1 TCID 50 ratios, ± 
standard deviation at 1:1 and 1:0.1 TCID 50 ratios.  
 
‡  Fitness difference (fold difference) WD = WM/WL, where: WM = relative fitness of more fit variant and WL 
= relative fitness of the less fit variant 
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We also compared the replication fitness of subtype A and C viruses between PBMC 
from US and Indian donors. For this purpose we first examined the kinetics of viral replication in 
monoinfections of PHA-stimulated PBMC from 13 Indian blood donors and 6 US blood donors. 
Results showed no significant difference in the replication kinetics of subtype A and C viruses 
between US and Indian blood donors (data not shown). We then performed GCAs using PBMC 
from 2 Indian donors and 3 pairs of subtype A and C viruses with known degrees of fitness 
differences in PBMC of US blood donors. Our results showed that there was no significant 
difference in the overall WD values between US donors and Indian donor 1 (p = 0.39, t test) or 
US donors and Indian donor 2 (p = 0.45, t test) (Table 6 and 7). There was also no significant 
difference in fitness between Indian donors 1 and 2 (p=0.12, t test). We did however observe a 
considerable difference in replication fitness among US donor 1 and both Indian donors for the 
A15 vs C31 competition pair at day 7. In this group, the WD for US donor 1 was 175.5 while the 
WD in Indian donors 1 and 2 were 9.5 and 23.1, respectively. This variability is not surprising 
considering that PBMC from each individual will support different levels of virus replication. 
But even with this variation the overall replication fitness of subtype C is higher than subtype A 
in PBMC from US and Indian blood donors.  
29.70.04.6 ± 0.040.2 ± 0.01C59:A11 
23.10.04.5 ± 0.650.2 ± 0.08C31:A15 
4.40.22.4 ± 0.210.5 ± 0.07C31:A6 Indian Donor 2
18.40.14.1 ± 2.040.2 ± 0.24C59:A11 
9.50.13.2 ± 2.870.3 ± 0.33C31:A15 
2.20.51.3 ± 0.240.6 ± 0.03C31:A6 Indian Donor 1
Relative WD(C/A) ‡Relative WD(A/C) ‡Relative WC †Relative WA †GCA Pairs
 
Relative fitness values (W) and fitness fold difference values (WD) were calculated as described for Table 6. 
Table 7. Relative fitness and relative fitness fold difference values of day 7 GCA using PBMC from Indian donors 
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5.5.4 Replication fitness and transmission efficiency of subtype A and C viruses using an 
ex vivo organ culture.    
The preponderance of adult HIV-1 infections in India is due to heterosexual contact. Using a 
cervical tissue-derived organ culture we investigated the transmission across cervical mucosa of 
subtype A and C virus by dually infecting cervical tissue with either primary isolates or 
molecularly cloned HIV-1.  After 3 days of exposure the level of transmitted virus across the 
cervical mucosa into the bottom well supernatant was measured by TaqMan® real-time RTPCR. 
Our results show that in 4 out of 6 primary isolate pairs tested, in 6 different cervical tissue 
specimens, subtype C virus had higher transmission efficiency (replication fitness) than subtype 
A virus (Figure 24). The fitness difference (WD) for subtype C viruses ranged from 0.72 – 47.03, 
while the WD for subtype A viruses ranged from 0.02 – 1.49. For two transmission pairs, 
A11:C31 and A6:C31 subtype A showed slightly higher transmission efficiency than subtype C. 
However, the subtype A WD values for A11 and A6 were relatively low (range 1.31 - 1.49) 
compared to the WD values for subtype C isolates (range 1.79 - 47.03) which showed higher 
transmission efficiency than subtype A. The subtype C primary isolate C31, which was 
outcompeted by subtype A in cervical tissue, also had the lowest WD value in PBMC GCA 
(Table 6). These findings imply that subtype C has higher overall transmission efficiency than 
subtype A although in some cases subtype A may be better transmitted to some extent.  
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Figure 24. Transmission efficiency of subtypes A and C primary isolates across cervical mucosa  
Transmission efficiencies are expressed as fitness difference (fold difference). 
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5.5.5 Determination of HIV-1 genomic regions responsible for enhanced replication 
fitness.  
Recent reports have suggested that replication fitness may be mediated by the viral envelope 
gene (52, 106, 107). To investigate this possibility we constructed half-genome chimeric virus by 
replacing the 3’-half (tat-3’ LTR) of an HIV-1 subtype A molecular clone (p1579A-1) with an 
equivalent  3’ half of a subtype C clone (pIndieC1) from India to generate a full length A/C 
chimeric clone as described in the Materials and Methods section. The A/C chimeric virus was 
then tested against the parental subtype A virus in GCA using PMBC. As shown in Figure 25 at 
day 14, p1579A-1 out competed the A/C chimeric clone in the GCA. However, the A/C chimera 
outcompeted subtype C pIndieC1 in CGA. These results would suggest that genomic elements in 
the 3’-half of subtype C are not attributable to replication fitness differences between subtype A 
and C virus of Indian origin. 
We also investigated the differences in transmission efficiency of parental clones and 
chimeric A/C virus. When tissues were dually infected with subtype A/C chimeric and parental 
subtype A (p1579A-1) virus we observed results similar to those obtained in GCA using PBMC 
in which the subtype A appeared to have higher transmission efficiency  than the chimeric clone 
which contained the 3’ half (tat – 3’LTR) of subtype C (Figure 26). However, when tissues were 
dually infected with parental subtype C clone and A/C chimera, the subtype C pIndieC1 had 
lower transmission efficiency than the A/C recombinant. These results suggest that the 3’-half of 
the genome works collectively with genes in the 5’-half of the genome to impart higher 
replication fitness.   
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Figure 25. Replication fitness of parental and half genome chimeric cloned viruses. Replication fitness is expressed as fitness fold difference 
(WD) of each HIV-1 variant in a GCA performed in PBMC.  
 
A schematic representation of HIV-1 parental and half genome clone is shown below the graph. 
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Figure 26. Transmission efficiency of subtypes A and C cloned virus and A/C chimeric virus across cervical mucosa.   
  
Fitness fold difference (WD) for each competition pair is indicated in the diagram below the graph.   
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5.5.6 Investigation of a trans suppressive mechanism of subtype A replication by subtype 
C in in vitro GCA.  
As shown above we have observed that HIV-1 subtype C outcompeted HIV-1 subtype A in the 
GCA. We investigated the possibility of whether such competition of subtype A by subtype C 
virus is mediated through a trans suppressive mechanism of subtype A by a soluble factor 
secreted by subtype C infected cells.  We tested this by growing subtype A virus in the presence 
of virus-free culture supernatant from subtype C-infected cells with or without pretreatment with 
such culture supernatant.  
We observed that virus-free culture supernatant from monoinfected subtype C PBMC did 
not suppress the growth of subtype A, regardless of whether the cells were preincubated with the 
culture supernatant (Figure 27). In fact, the subtype C virus-free culture supernatant induced 
non–specific activation of cells and promoted increased growth of subtype A virus compared to 
cells infected with subtype A virus and cultured in IL-2 media only. As a control, virus-free 
culture supernatant from subtype A infected cells also did not suppress growth of subtype A 
virus, but rather promoted increased growth of subtype A virus. Such activation of viral growth 
did not occur in the presence of cell culture supernatant from uninfected cells. These results 
indicate that soluble factors such as gag matrix proteins or capsid protein which are produced in 
abundance from virus infected cells such as those infected by subtype C virus are not responsible 
for competitive growth of HIV-1 subtype C over subtype A in the GCA. 
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Day 7 Trans Suppression Assay of subtype A by subtype C 
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Cells were either pretreated with virus-free supernatant or not pre-treated, followed by infection with HIV-1 subtype A then cell culture in the presence of 
increasing percentages of the final culture volume of virus-free supernatant. Infect only indicates cells that were infected with HIV-1 subtype A and not pre-
treated or grown in the presence of virus-free supernatant. Negative controls included 1) pre-treatment, culture in the presence of virus-free supernatant and no 
infection; 2) no pre-treatment, culture in the presence of virus-free supernatant and no infection and 3) cells only, no infection. All negative controls showed no 
virus growth as determined by HIV-1 p24 assay (p24 ≤ 30pg/ml at day 14, data not shown).  
Figure 27. Trans suppression of HIV-1 subtype A by virus-free supernatant from infected cells or by culture supernatant from uninfected cells. 
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5.6 DISCUSSION 
There is a growing body of data supporting the hypothesis that the differential spread of HIV 
variants, groups and subtypes in the human population may be related to differences in 
replication fitness and transmission efficiency (51, 52, 54, 58, 77). The seminal study of 
Quinones-Mateu et al found that there is a correlation between ex vivo fitness and disease 
progression. This study was useful in demonstrating that fitness values may serve as a predictor 
of progression to AIDS. These studies form the basis that in vitro replicative fitness data can be 
used to study the interaction between two subtypes in transmission and disease progression. 
 Recently using a GCA assay, Arien et al assigned an order of relative fitness to all 
classes of HIV viruses: HIV-1 group M > HIV-2 >HIV-1 group O. This study implied that the 
lower replicative capacity of group O and HIV-2 compared to group M viruses may have led to 
decreased transmission and distribution of these groups in the human population. In a recent 
study, ex vivo replicative fitness of CRF02_AG isolates was found to be higher than subtype A 
and G viruses from the same geographic region and was independent of the co-receptor tropism 
and irrespective of high or low CD4+ T cell count (55). Over the last ten years CRF02_AG has 
become the predominant subtype in West and West Central Africa. These results suggest that 
replicative fitness may have contributed to the dominant spread of CRF02_AG over A and G 
subtypes in West and West Central Africa (55).  
Genetic analysis of HIV-1 circulating in different parts of India at different times in the 
last fifteen years indicates that the subtype C predominates in India with a small proportion of 
infection caused by subtypes A or B (13, 24, 27, 31, 129).  These Indian HIV-1 are of CCR5 
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tropism with a NSI phenotype even when they are isolated at late stages of infection (13, 110). 
Additionally, we have shown that HIV-1 subtype C from India is distinct from other HIV-1 
subtypes C around the world, like those from Africa and South America. HIV-1 infection in 
some parts of Africa started predominantly with subtype C, but later other non-C subtypes 
emerged to account for as much as 40% of circulating subtypes in that region.  In contrast, HIV-
1 subtype C in India has predominated over other subtypes throughout the entire epidemic and 
regardless of the geographic area (13, 24, 27, 31, 37, 129). Our results indicate that PBMC from 
the Indian population do not support higher replication of subtype C as compared to subtype A of 
Indian origin, indicating that genetics of the Indian population may not be responsible for the 
asymmetric distribution of subtype C over other subtypes in India. This distinct asymmetric 
distribution of HIV-1 subtypes in India suggests that there may be a biological basis for such 
dissemination. The mechanism for such an asymmetric distribution could be due to any one or 
combination of factors including replication fitness, transmission efficiency and founder effect. 
In this report we have examined the first two possibilities using subtype A and C from India.   
We have used a CGA assay in CD8-depleted PBMC to study replicative fitness among 
these two subtypes. Our data indicate that among 11 subtype A and C pairs tested, all primary 
subtype C isolates had higher replicative fitness (mean fitness score of 57.7) than subtype A 
isolates when cells were dually infected at a ratio of 1:1. Even at 10-fold less inoculum than 
subtype A, subtype C isolates outcompeted subtype A in most cases. These results demonstrate 
that subtype C HIV-1 isolates from India have higher replicative fitness than subtype A from 
India in PBMC. Such replicative fitness of subtype C over subtype A also has been extended to 
PBMC of Indian origin, indicating that such replicative fitness of subtype C is independent of 
ethnic origin.   
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These data contradict the results obtained by Arien et al (53), in which subtype C viruses 
from Africa were found to be the least fit among all HIV-1 group M viruses in GCAs performed 
using PBMC and in an vitro DC-T cell transmission model.. This could be due to that fact Indian 
subtype C is different than subtype C from Africa and South America.. Since Langerhans cells in 
cervical mucosa have been implicated for HIV-1 transmission across cervical mucosa, we 
examined replicative fitness between subtype A and subtype C from India in a cervical tissue 
derived organ culture. Use of cervical tissue derived organ culture provides direct measurement 
of HIV transmission across the cervical mucosa. Our data indicate that in 4 out of 6 pairs tested, 
subtype C had higher transmission efficiencies than subtype A. Two pairs (A6:C31 and 
A11:C31) in which subtype C had shown lower transmission efficiency than subtype A, also 
showed relatively lower replicative fitness scores (3.3 and 4.7, respectively) in PMBC as 
compared to other competing pairs (mean 57.7). These observations along with recent a report 
demonstrating a correlation between subtype C infected women and increased vaginal shedding 
of virus (58) and another describing compartmentalization of subtype C virus in the cervix of a 
woman dually infected with subtype A and C viruses (130), indicate that subtype C may have 
transmission advantages which could have influenced its spread throughout India and regions of 
Africa. 
To understand the molecular mechanism of higher in vitro replicative fitness of subtype 
C over subtype A, we have examined a trans mechanism for higher replication fitness subtype C 
by which a soluble factor(s) secreted by subtype C infected cells confer suppression of subtype A 
replication.  Our data indicate that virus-free culture supernatant from monoinfected subtype C  
PBMC did not suppress the growth of subtype A, regardless of whether the cells were 
preincubated with the culture supernatant or not. In fact, the subtype C virus-free culture 
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supernatant induced non–specific activation of cells and promoted increased growth of subtype 
A compared to cells infected with subtype A and cultured in IL-2 media only.  
We examined the role of LTR and envelope gene to elucidate a cis mechanism of higher 
replicative fitness of subtype C over subtype A. In a previous study we have shown that there 
was no significant difference in the structure and function of the LTR between subtypes A and C 
from India even though subtype C was predicted to have an additional NF-κB site (Rodriguez et 
al, ARHR in press). To understand the role of envelope gene, we have constructed recombinants 
between subtype A and subtype C in which the 3’ half of the subtype A has been replaced with 
subtype C. A competition between this recombinant and parental wild type subtype A and C in a 
GCA assay and transmission assay across the cervical mucosa indicate that the 3’-half of the 
genome is not directly responsible for differences in replication fitness. In addition, the increased 
fitness of the A/C chimera over subtype C may indicate the possible fitness and epidemic 
potential of an A/C recombinant having this genomic structure, should one emerge in India. To 
date, only one A/C recombinant has been reported in India (ref). This is most likely due to the 
low frequency of subtype A viruses circulating in the country and to HIV-1 subtype 
determination restricted to specific regions of the genome. Further investigations of HIV-1 
recombinant viruses circulating in India would help to shed light on the possible emergence of a 
recombinant virus variant of this nature. Finally, the higher replicative fitness and increased 
transmission across the mucosa of subtype C over subtype A may be due to a more complex 
interaction between the genes located within both halves of viral genome. 
The data supporting a correlation between in vitro viral replication fitness in PBMC and 
the global distribution and epidemiologic spread of HIV is continuously expanding. Our 
investigation sheds new light on the potential role of replication fitness and transmission 
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efficiency to the asymmetric distribution of HIV-1 subtypes in India. This study also shows that 
HIV-1 subtypes with higher fitness could have a replication advantage over other subtypes which 
may shape the epidemic and current global subtype distribution. 
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6.0  OVERALL DISCUSSION AND FUTURE DIRECTIONS 
6.1 SUMMARY OF FINDINGS 
Genetic analysis of HIV-1 circulating in different parts of India at different times in the last 
fifteen years indicates that subtype C predominates with a small proportion of infections caused 
by subtypes A or B. Furthermore, HIV-1 subtype C from India has been shown to be distinct 
from other HIV-1 subtype C around the world, like those from Africa and South America. The 
distinct asymmetric distribution of HIV-1 subtypes in India suggests that there may be a 
biological basis for such dissemination of HIV-1 subtypes. Based on studies showing a 
correlation between in vitro replication fitness and disease progression and those suggesting a 
correlation between replication fitness and HIV-1 subtype geographic distribution, we 
hypothesized that the HIV-1 subtype C from India would display higher in vitro replication 
fitness than subtype A from India. To investigate this hypothesis we developed the following 
specific aims: 1) to construct and characterize an infectious molecular clone of HIV-1 subtype A 
of Indian origin; 2) to evaluate the replication fitness of HIV-1 subtypes A and C from India 
using an in vitro growth competition assay; 3) to compare the transmission efficiency of HIV-1 
subtypes A and C from India across the mucosa of cervicovaginal tissue; and  4) to evaluate the 
role of the LTR and env in replication fitness and transmission efficiency across cervicovaginal 
tissue. 
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 The study in chapter one describes the construction of an HIV-1 subtype A infectious 
molecular clone of Indian origin. To do this we cloned, sequenced and characterized virus from 
an HIV-1 subtype A primary isolate from India. We determined that the clone, p1579A-1, is 
replication competent in primary cells, that it uses CCR5 as its cellular coreceptor to gain entry 
into permissive cells and that it has a non-syncytium inducing phenotype, indicating low 
pathogenic potential. The p1579A-1 envelope gene was also found to have DNA and amino acid 
sequences similar to those found in HIV-1 subtypes A1 and A2 from other parts of the world. 
Additionally, we also found similarity in the number of potential N-linked glycoslylation sites 
within env between p1579A-1 and other subtype As. This study was the first of its kind to 
delineate and characterize the complete genomic sequence of an HIV-1 subtype A from India. 
Availability of this clone will be useful for the study of replication dynamics and evolution of 
subtypes in India and for characterizing other subtype A around the world.  
The studies presented in chapter two were designed to characterize the structure and 
function of the LTR region to determine whether the predominance of subtype C is due to higher 
functional attributes of subtype C LTR compared to other subtypes in India. To do this we PCR 
amplified the long terminal repeat (LTR) region from a panel of subtype A and subtype C 
primary isolates and infectious molecular clones and cloned them into a reporter construct for 
functional analysis. The most notable structural difference that was observed was an additional 
NF-κB binding site in subtype C LTRs that was not predicted for subtype A LTRs. However, 
despite this additional enhancer motif, we did not observe any significant difference in the 
transcriptional activity between subtype A and subtype C LTRs either in the presence or absence 
of viral tat protein or after stimulation with TNF-alpha or PMA. These results were unexpected 
since several studies have reported functional differences between the LTRs of HIV-1 subtypes 
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from several different regions of the world under similar conditions (98, 104, 131, 132). 
However, in our study, no significant differences have been reported between subtypes A and C 
from India. These results suggest that replication capacity of Indian HIV-1 subtypes is not solely 
dependent on transcriptional events and that there is a more complex interplay of virus and host 
cell factors which determine the rate and extent of virus production.  
The studies in chapter three sought to investigate the in vitro replication fitness of 
subtypes A and C of Indian origin in an effort to understand the mechanism of subtype C 
predominance in India. Using a dual infection growth competition assay (GCA) and a panel of 
subtype A and subtype C primary isolates and infectious molecular clones of both subtypes, we 
found that subtype C primary isolates outcompeted subtype A primary isolates in PBMC by as 
much a 255-fold when competed at equal infectivity. Likewise, using an ex vivo cervical tissue 
derived organ culture transmission model which closely mimics the in vivo cervicovaginal tissue 
architecture, the majority of subtype C displayed higher transmission efficiency than subtype A. 
We also observed that there was no significant difference in overall fitness values when 
competitions were performed using US or Indian PBMC. This result served to rule out the 
possibility of genetic factors that could be predisposing the Indian population to support higher 
subtype C replication.  
This investigation reports genetic and functional characterization of HIV-1 subtype A and 
subtype C of Indian origin which has contributed new HIV-1 genomic sequence information that 
is important for characterizing HIV-1 subtypes and which may be necessary for design of 
subtype-specific vaccines and antiviral compounds. Additionally, this investigation sheds new 
light on the potential role of replication fitness and transmission efficiency as contributing 
factors to HIV-1 subtype distribution in India. Here, unlike previous findings, in which subtype 
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C has been shown to be the least fit among all HIV-1 group M subtypes, we report a higher 
replication fitness of subtype C over subtype A. This has implications to the unique properties of 
subtype C from India compared to other HIV-1 group M subtypes. Based on the findings from 
this study we propose an epidemiological disease model for India in which HIV-1 subtype C has 
acquired higher replication capacity and increased transmissibility compared to subtype A. These 
properties have been advantageous and beneficial for subtype C spread throughout human hosts 
in India and has resulted in the current predominance of subtype C in India.  
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6.2 PUBLIC HEALTH SIGNIFICANCE 
HIV-1 is a rapidly mutating and highly adaptable pathogen which results in an increase in viral 
genetic diversity and potentially an evolutionary edge (11). This high genetic diversity has 
resulted in multiple subtypes, circulating recombinant forms (CRF), unique recombinant forms 
(URF) and intrapatient quasispecies. This variability highlights the difficulty and importance of 
obtaining broad protection against HIV-1 in the form of vaccines, antiviral drugs and 
microbicides. The findings presented in this study have increased our understanding of the 
mechanism of asymmetric distribution of HIV-1 subtypes in India by highlighting the 
importance and uniqueness of HIV-1 subtypes of Indian origin. As we have described in this 
work, HIV-1 subtype C of Indian origin has higher replication fitness and increased 
transmissibility compared to subtype A of Indian origin. Therefore, control strategies, such as the 
design and use of antiviral compounds, in India should be predominantly geared towards subtype 
C since it may continue to predominate over subtype A and other subtypes circulating in this 
country. As well, vaccine and antiviral compound design efforts should encompass all regions of 
the genome since we have shown that the envelope gene may not be the only determining factor 
of replication and transmission differences. Although a direct correlation has not been made 
between in vitro replication fitness and global subtype distribution, investigations of fitness 
differences among HIV-1 subtypes in India should be ongoing. Our findings that A/C 
recombinant virus had higher replication fitness than subtype C virus may be especially 
important for future projections considering that within the last 10 years, CRFs have become 
predominant in regions where two or more subtypes co-circulate (133). These types of studies 
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may be useful in forecasting the emergence of genetic variants with altered biologic properties 
that could eventually lead to their rapid spread and predominance. 
6.3 THE IMPORTANCE OF STUDYING HIV-1 SUBTYPES 
 
6.3.1 HIV-1 subtypes and neutralizing antibody responses 
Neutralizing antibodies (Nabs) against viral envelope proteins (env) provide the first line of 
adaptive immune defense against HIV-1 infection by blocking the infection of susceptible cells 
(134). Opposing studies have shown neutralization activities by serum samples and monoclonal 
antibodies (MAbs) against HIV-1 virus subtypes to be both cross-reactive (134-136) and subtype 
specific (91, 134). Recently Binley et al (134), conducted a large-scale and comprehensive 
investigation to evaluate MAbs from subtype B-infected donors and a subtype B HIV+ plasma 
against a panel of viruses from diverse backgrounds. Overall, MAbs directed against gp120 or 
gp41 or the CD4 binding domain exhibited greater activity against subtype B than non-B viruses. 
Out of eight MAbs tested, only two, b12 and 4E10, both directed at the CD4 binding site, were 
effective against subtype C viruses. Based on this study it seems important to continue to 
investigate neutralizing antibody responses to non-B subtype viruses to determine those that are 
the most broadly reactive. This is especially true in the case of subtype C which is the most 
predominant subtype worldwide.  
  121
6.3.2 HIV-1 subtypes and cell-mediated immune responses 
It is generally accepted that cross-reactive cytotoxic T lymphocytes are present in individuals 
infected by non-B subtypes (137, 138). However, intrasubtype CTL responses are usually 
stronger and more frequently detected than cross-clade (subtype) reactivities (5). Furthermore, 
differences in the frequency and relative magnitude of subtype-specific responses has been 
reported (139). These differences were generally observed based on the level of 
diversity/conservation of the epitope. Subtype-specific CTL epitopes have also been reported 
(140). Despite the observed subtype cross-reactive responses, a successful vaccine has not been 
developed.  
6.3.3 HIV-1 subtypes and drug resistance 
Virtually all available evidence suggests that all HIV-1 subtypes display similar sensitivities to 
antiviral drugs, but viruses from some subtypes may have a greater propensity to develop 
resistance to certain drugs or may contain inherent variability rendering them resistant (141). 
Most available antiretroviral drugs are directed towards the RT (reverse transcriptase) and PR 
(protease) proteins of Pol and are based on HIV-1 subtype B sequences (141). Variations in these 
regions may therefore affect drug susceptibility and the development of drug resistance. In the 
case of subtype C viruses, studies have reported more rapid selection of resistance variants to 
NNRTI and significantly lower concentration of drug required for development of resistance to 
NNRTIs as compared to subtype B (142-144). There have also been reports of development of 
novel resistance mutations of subtype C isolates to the NNRTIs nevirapine and efavirenz (142). 
In addition diminished drug sensitivity due to rapid growth kinetics has been reported for other 
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HIV-1 subtypes (145). These findings are especially significant due to the substantial number of 
people living with HIV/AIDS in developing countries that likely do not have access to highly 
active antiretroviral therapy (HAART). 
6.3.4 HIV-1 and microbicides 
Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal 
of preventing or reducing the transmission of sexually transmitted diseases including HIV-1 (62, 
67). The development of a microbicide against HIV-1 is especially important since the majority 
of HIV-1 infections are transmitted sexually. If effective, a microbicide may offer an alternative 
method of protection to a vaccine which to date, has not been developed and may take several 
more years. There is very little data comparing HIV-1 subtype and microbicide activity. One 
study which reported the antiviral activity of commercial microbicides against HIV-1 subtypes 
A, B and C reported similar activity of each microbicide against each HIV-1 variant (167). In 
some cases however, subtype C virus infection was inhibited the least compared to the other 
subtypes. 
Microbicides can be classified by their primary mechanism of action. Vaginal defense 
enhancers help maintain the vaginal pH in an acidic range or facilitate colonization of vaginal 
flora with lactobacilli (67). Agents that act in this respect are Acidform™(146), 
BufferGel™(147), and Lactobacilli (Lactobacillus crispatus)(148-150).  
Surfactants or detergents disrupt microbial cell membranes. While they can be effective 
against the HIV-1 membrane, surfactants can also disrupt cell membranes which can lead to 
toxicity thus increasing the risk of infection. Unfortunately this was the situation observed in 
clinical trials of the surfactant Nonoxynol-9 (N-9) leading to its termination as a potential 
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microbicide (151, 152). Other surfactants that have been better tolerated than N-9 are C31G 
(Savvy™) (153, 154) and the Invisible condom™ (sodium lauryl sulfate, SLS) (155). Of these 
two, SLS, whose mechanism involves a combination of solubilization of viral envelopes and 
denaturation of envelope or capsid proteins; is currently in a phase 1/2 study (156). Each of the 
above mentioned agents have the potential to perform equally well against various HIV-1 
subtypes.   
Entry or fusion inhibitors target viral epitopes or cell receptors to prevent infection of 
cells. The agents that are particularly directed against viral epitopes probably have the most 
potential to display varying degrees of efficacy due to the highly variable nature of HIV – 
especially in the envelope gene. Entry inhibitors directed against viral epitopes in gp120 or gp41 
include polyanions such as PRO-2000 (157), Dextrin sulfate (158-160), Cellulose sulfate (161), 
carrageenans (Carraguard™) (162) and cellulose acetate phthalate (CAP) (163). Cyanovirin-N 
(CV-N) is an agent that binds high mannose residues in the HIV envelope preventing fusion with 
the host cell membrane. CV-N would probably be more effective against a broad range of HIV-1 
subtypes however the cost of this agent for optimal protection is probably unrealistic for the 
target population in greatest need. PSC-RANTES is a second generation synthetic CCR5 
antagonist. In vitro studies using PBMC targets have shown that it is active against all HIV 
subtypes (164) and studies in macaques displayed protection against vaginal challenge with a 
SHIV isolate (157).  
Finally, replication inhibitors act by preventing reverse transcription of the viral RNA 
genome. Reverse transcriptase (RT) inhibitors can be delivered topically or orally. These types 
of agents include Tenofovir (67) and UC-781 (165). There are several advantages to the use of 
these drugs as microbicides, however the major disadvantage is the possibility of the emergence 
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of drug resistant mutants.  As discussed above in section 6.2.3, subtype C viruses may respond 
differently to these drugs and may have a propensity to develop resistance mutations sooner than 
other HIV-1 subtypes.  
Taken together our findings highlight the importance of continued investigation and 
characterization of genetic differences of HIV-1 subtypes and how these differences could affect 
replication capacity which in itself could prompt the emergence of immune escape and drug 
resistant variants.  
6.4 FUTURE DIRECTIONS 
6.4.1 Construction of env recombinant viruses  
There are only a few recent studies which have shown that replication fitness is mediated by env. 
Using an HIV-1 neutral backbone such as pNL4-3 or HXB2, a comprehensive panel of Indian 
subtype A and subtype C env recombinant clones can be generated to investigate differences in 
replication fitness solely based on env. Additionally, env chimeras can be constructed to 
determine the region of the envelope gene responsible for enhanced replication fitness. 
Subsequently point mutations can be made to pinpoint DNA and amino acid sequences involved 
in this mechanism/fitness advantage.  
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6.4.2 Investigation of early timepoints in fitness  
We have reported that the “winner” in a dual infection is generally determined by day 7 when 
two variants are competed at equal TCID 50 ratios. We do not know however, the nature of viral 
dynamics at early timepoints. Has the winner already been determined after the first round of 
replication or does it take several hours or days? Investigations into the early events during the 
competition would address these concerns. As well, looking into the amount of virus that has 
infected cells at early timepoints by quantitation of viral RNA inside cells would explain if it is 
viral burst size from infected cells that allows the winner an advantage over the outcompeted 
variant.  
 
6.4.3 Continuing investigations of the long terminal repeat  
Several studies have reported differences in the transcriptional activity of HIV-1 subtype-specific 
LTR based on cell type, host cell signaling pathways and tat protein transactivation. 
Macrophages are also an important subset of cells found in the subepithelial mucosa that are 
susceptible to HIV-1 infection by CCR5 using viruses. LTR reporter constructs can be 
investigated in macrophages, using a subtype-matched tat protein and in the presence of 
biologically relevant concentrations of stimuli for transcriptional activity.   
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6.4.4 Replication fitness in different cell types 
As discussed for the LTR, it is also important to investigate the replication fitness dynamics of 
primary isolates in other cell types such as macrophages. These cells are present in the cervical 
mucosa and blood and would also elucidate mechanisms of in vivo replication fitness 
differences. 
6.4.5 Subtype C response to antiretroviral compounds  
The foundation of all of these investigations is to make significant contributions to the field of 
HIV-1 research which would aid in therapeutic drug and vaccine design. Therefore based on the 
data presented here the response of HIV-1 subtype C viruses of Indian origin to antiretroviral 
drugs and microbicides is a next logical step. It may be revealed that not only is Indian subtype C 
genetically and functionally unique from other subtype C but that it also displays a unique 
pattern of drug recognition and/or resistance. This type of investigation would put into 
perspective the additional importance of necessary compounds designed specifically for subtype 
C of Indian origin. This should be of the highest priority given the vast number of people in India 
infected with this subtype of HIV-1.  
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